2014N209329_00 CONFIDENTIA L
GlaxoSmithKline group of companies BTZ116849
1TITLE PA GE
Division:   Worldwide Development
Information Type: Clinical Protocol
Title: APhase I, Open -Label, Single -Dose, Multi -Part Study  to Assess 
the Pharmacokinetics of Gepotidacin ([COMPANY_004]2140944) in Male 
and Female Adult Subjects with Vary ing Degrees of Renal 
Impairment and in Matched Control S ubjects with Normal Renal 
Function
Compound Number: [COMPANY_004]2140944
Development Phase I
Effective Date: 01-MAR -2016
Authors:
[COMPANY_004] Authors:  (Clinical Pharmacology  Modeling and Simulation), 
 (Inv estigative Safety  and Drug Disposition),  (ID, Medicines 
Discovery  and Development),  (Clinical Statistics), and  (Clinical 
Pharmacology ).
[COMPANY_003] Authors:  ( Pharmacokineticist),  (Biostatistician),  
(Glob al Product Development),  (Global Product Development), and 
 (Medical Writer)
Copy right 2
016 the GlaxoSmithKline group of companies. All rights reserved. 
Unauthorized copying or use of this information is prohibited. 2016N307631_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
 2016N307631_00
[COMPANY_003]
[COMPANY_003]
2014N209329_00 CONFIDENTIA L
BTZ116849
3MEDICA L MONITOR /SPONSOR INFORM ATION PA GE
Medical Monitor /Serious Adverse Event Contact [CONTACT_7171]:
Role Name [CONTACT_387071] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberClinic Address
Primary 
Medical 
Monitor and 
SAE contact 
[CONTACT_589347]: Safety fax 
number:[COMPANY_003]
[ADDRESS_776213]
Collegeville, PA [ZIP_CODE], 
[LOCATION_003]
Sponsor Legal Registered Address:
GlaxoSmithKline Research & Development Limited
[ADDRESS_776214] Address: 
GlaxoSmithKline 
[ADDRESS_776215] 
[PO_BOX]
Collegeville, PA  [ZIP_CODE] -0989
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].
Regulatory  Agency  Identify ing Number : IND 111885 2016N307631_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2014N209329_00 CONFIDENTIA L
BTZ116849
4INVESTIGA TOR PROTOCOL A GREEMENT PA GE
I confirm agreement to conduct the study  in compliance with the protocol.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described stud y.
I agree to ensur e that all associates, colleagues ,and employ ees assisting in the 
conduct of the stud y are informed about their obligations. Mechanisms are in place 
to ensure that site staff receive sthe appropriate information throughout the study .
Investigator Name:
[CONTACT_217750] 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
5TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY BTZ116849 ................................................. 8
2.INTRODUCTION .................................................................................................... 12
2.1. Study Rationale .......................................................................................... 12
2.2. Brief Background ................................
........................................................ 12
3.OBJECTIVES AND ENDPO INTS ........................................................................... 13
4.STUDY DESIGN .................................................................................................... 13
4.1. Overall Design ............................................................................................ 13
4.2. Treatment Arms and Duration ..................................................................... 15
4.3. Type and Number of Subjects ..................................................................... 16
4.4. Design Justification ..................................................................................... 17
4.5. Dose Justification ........................................................................................ 17
4.6. Benefit:Risk Assessment ............................................................................ 18
4.6.1. Risk Assessment ......................................................................... 19
4.6.2. Benefit Assessment ..................................................................... 21
4.6.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_776216] AWAL CRITERIA ............. 21
5.1. Inclusion Criteria ......................................................................................... 21
5.2. Exclusion Criteria ........................................................................................ 23
5.3. Screening/Baseline/Run -in Failures ............................................................ 25
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 25
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 25
5.4.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................. 26
5.4.3. Gastrointestinal Stoppi[INVESTIGATOR_2121] ................................................ 26
5.4.4. Rash/Hypersensitivity Stoppi[INVESTIGATOR_2121] ....................................... [ADDRESS_776217] and Other Study Treatment .................................... 27
6.2. Treatment Assignment ................................................................................ 27
6.3. Planned Dose Adjustments ......................................................................... 28
6.4. Blinding ....................................................................................................... 28
6.5. Packaging and Labeling .............................................................................. 28
6.6. Preparation/Handling/Storage/Accountability .............................................. 28
6.7. Compliance with Study Treatment Administration ....................................... 29
6.8. Treatment of Study Treatment Overdose .................................................... 29
6.9. Treatment after the End of the Study .......................................................... 30
6.10. Lifestyle and/or Dietary Restrictions ............................................................ 30
6.10.1. Meals and Dietary Restrictions .................................................... 30
6.10.2. Caffeine and Alcohol .................................................................... 30
6.10.3. Activity ......................................................................................... 30
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 30
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 30
6.11.2. Prohibited Medications and Nondrug Therapi[INVESTIGATOR_014] ........................... 31
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 31 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
67.1. Time and Events Tables ............................................................................. 33
7.2. Screening and Critical Baseline Assessments ............................................ 41
7.3. Safety ......................................................................................................... 41
7.3.1. Adverse Events and Serious Adverse Events .............................. 41
[IP_ADDRESS]. Time period and Frequency for collecting
Adverse Event and Serious Adverse Event 
information ................................................................ .41
[IP_ADDRESS]. Method of Detecting Adverse Events and 
Serious Adverse Events ............................................. 42
[IP_ADDRESS]. Follow -up of Adverse Events and Serious 
Adverse Events .......................................................... 42
[IP_ADDRESS]. Regulatory Reporting Requirements for 
Serious Adverse Events ............................................. 42
7.3.2. Pregnancy ................................................................................... 42
7.3.3. Physical Exams ........................................................................... 43
7.3.4. Vital Sign s.................................................................................... 43
7.3.5. Electrocardiogram ........................................................................ 43
7.3.6. Clinical Safety Laboratory Assessments ...................................... 43
7.4. Pharmacokinetics ....................................................................................... 4
4
7.4.1. Blood Sample Collectio n.............................................................. 44
7.4.2. Urine Sample Collection .............................................................. 45
7.4.3. Saliva Sample Collection ............................................................. 45
7.4.4. Dialysate Sample Collection ........................................................ 45
7.4.5. Sample Analysis .......................................................................... 45
7.5. Optional Pharmacokinetic Markers ............................................................. 46
7.6. Genetics ..................................................................................................... 46
8.DATA MANAGEMENT ........................................................................................... 46
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .46
9.1. Hypotheses ................................................................................................ .46
9.2. Sample Size Considerations ....................................................................... 47
9.2.1. Sample Size Assumptions ........................................................... 47
9.2.2. Sample Size Re- estimation or Adjustment ................................... 47
9.3. Data Analysis Considerations ..................................................................... 47
9.3.1. Analysis Populations .................................................................... 47
9.3.2. Interim Analysis ........................................................................... 47
9.4. Key Elements of Analysis Plan ................................................................... 48
9.4.1. Primary Analyses ......................................................................... 48
9.4.2. Secondary Analyses .................................................................... 50
[IP_ADDRESS]. Safety Analyses .......................................................... 50
9.4.3. Other Analyses ............................................................................ 51
[IP_ADDRESS]. Exploratory Analyses .................................................. 51
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 51
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 51
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 51
10.3. Quality Control (Study Monitoring) .............................................................. 52
10.4. Quality Assurance ....................................................................................... 53
10.5. Study and Clinic C losure ............................................................................. 53
10.6. Records Retention ...................................................................................... 53 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
710.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 54
11.REFERENCES ....................................................................................................... 55
12.APPENDICES ........................................................................................................ 57
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 57
12.2. Appendix 2: Liver Chemistry Stoppi[INVESTIGATOR_2121] ............................................ 59
12.3. Appendix 3: Liver Safety Required Actions and Follow -up 
Assessments .............................................................................................. 60
12.4. Appendix 4: Genetic Research ................................................................... 62
12.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 65
12.5.1. Definition of Adverse Events ........................................................ 65
12.5.2. Definition of Serious Adverse Events ........................................... 66
12.5.3. Definition of Cardiovascular Events ............................................. 67
12.5.4. Recording of Adverse Events and Serious Adverse Events ......... 68
12.5.5. Evaluating Adverse Events and Serious Adverse Events ............. 68
12.5.6. Reporting of Serious Adverse Events to [COMPANY_004] .............................. 69
12.6. Appendix 6: Division of Microbiology and Infectious Disease Adult 
Toxicity Tables for Adverse Event Assessment ........................................... 71
12.7. Appendix 7: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential and Collection of 
Pregnancy Information ................................................................................ [ADDRESS_776218] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproduc tive Potential ......................... 79
12.7.2. Collection of Pregnancy Information ............................................ 80
12.8. Appendix 8: Follow -up for Gastrointestinal Findings ................................... 82
12.9. Appendix 9: Clostridium Difficile Testing Procedure and Algorithm ............. 83
12.10. Appendix 10: Country -Specific Requirements ............................................. 84
12.11. Appendix 11: Physiologically Based Pharmacokinetic Model Input 
Parameters ................................................................................................ .85 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
81. PROTOCOL SYNOPSIS FOR STUDY BTZ116849
Rationale
This study  will be conducted to determine if altered renal function affects the plasma 
pharmacokinetics of gepotidacin, which will inform if dosing recommendations based 
upon renal impairment are req uired. The proposed single IV infusion dose of gepotidacin 
750 mg administered over 2 hours will provide an approximate 2.5 -fold margin for area 
under the plasma concentration -time curve (AUC) and maximum observed concentration 
(Cmax) based on the highest single IV dose of gepotidacin (1800 mg) evaluated in adult 
healthy  subjects.
Objectives /Endpoints
Objectives Endpoints
Primary
 To compare the pharmacokinetics of 
gepotidacin administered as a 750 -mg IV dose 
innormal healthy subjects compared with
subjects with mild, moderate, and severe renal 
impairment, and withsubjects with end -stage 
renal disease (ESRD) Plasma p rimary pharmacokinetic (PK) endpoints include 
AUC(0 -∞) and Cmax of gepotidacin, as data permit
 Urine primary PK end points include Ae total, fe%, and 
CLr of gepotidacin , as data permit
 Dialysate primary PK end points include AUC(t0- t1), CL D, 
and Frem% (0-4), of gepotidacin, as data permit
Secondary
 To assess the safety and tolerability of 
gepotidacin administered as a [ADDRESS_776219] 12-lead safety electrocardiogram readings, change from 
baseline in vital sign measurements (blood pressure and 
heart rate), monitoring of adve rse events, toxicity grading 
of clinical laboratory test results, and physical 
examinations
 To evaluate the secondary PK parameters of 
gepotidacin administered as a [ADDRESS_776220] Plasma PK endpoints include AUC(0 -t), CL,  z, t1/2, 
Tmax, Vss, and Vz , as data permit
 Urine PK endpoint includes Ae(t1 -t2), as data permit
 Dialysate PK endpoints include Arem(0 -1), Arem(1- 2), 
Arem(2 -3), Arem(3 -4), and Arem(0 -4), as data permit
Exploratory
 To evaluate the saliva pharmacokinetics of 
gepotidacin (subjects in Part 1 only) Primary PK endpoints include AUC(0 -∞) and Cmax of 
gepotidacin, as data permit
 Secondary PK endpoints include AUC(0 -t), CL, λz, t1/2, 
Tmax, Vss, and Vz, as data permit
ESRD = end -stage renal disease; PK = pharmacokinetic
Overall Design
This is a Phase I, nonrandomized, open- label, parallel -group, multi -center, multi -part 
study  that will evaluate the pharmacokinetics, safe ty, and tolerability  of a single IV dose 
of gepotidacin 750 mg over 2 hours in subjects with normal renal function, subjects with 
mild, moderate, and severe renal impairment, and subjects with end- stage renal disease 
(ESRD; on dialy sis and not on dialy sis).
Subjects will be enrolled into groups based on the classification as defined in the United 
States Food and Drug Administration draft guidance for industry , “Pharmacokinetics in 
Patients with I mpaired Renal Function 
–Study  Design, Data Anal ysis, and Impa ct on  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
9Dosing and Labeling” [ DHHS , 2010]. Subjects with normal renal function and subjects 
with renal impairment will be classified based on the estimated glomerular filtration rate 
(eGFR; based on the Modification of Di et in Renal Disease Study ). Subjects with normal 
renal function will also be classified based on estimated creatinine clearance (Clcr).
This will be a multi- part study , in which pharmacokinetic ( PK)requirements must be met 
(observed mean values: AUC <48ghr/mL and Cmax <14g/mL ); and safet y and 
tolerability  will be reviewed before enrolling subjects into the next part of the study .In 
Part 1, subjects with normal renal function ; subjects with moderate renal impairment; and
subjects with severe renal impairment and subjects with ESRD not on hemodialysis will 
be enrolled. In Part 2 (optional), subjects with normal renal function , subjects with mild 
renal impairment, and subjects with ESRD on hemodialy sis will be enrolled based on the 
PK, safet y,tolerabili ty, and data 
results of Part 1.
Subjects with renal impairment will be matched to subjects with normal renal function in 
terms of gender distribution, age (approximately  ±10 y ears), and body mass index 
(approximately  ±20%).
Treatment A rms and Duration
Subjects will be screened within 30 day s prior to entry  to the clinic and will be enrolled 
as follows:
Part 1:
Group A: subjects with normal renal function ( eGFR ≥90 mL/min/1.73m2)
Group B: subjects with moderate renal impairment (eGFR 30 to 59 mL/min/1.73m2)
Group C: subjects with severe renal impairment and subjects with ESRD not on 
hemodialy sis (eGFR <30 mL /min/1.73m2)
If PK, safet y, and tolerability  requirement s are not met in Part 1, and based on the 
emerging data, and/or data that are not expected to exceed the requirements in the 
subjects with ESRD on hemodialy sisor may  require dose adjustment , subjects for Part 2 
will be enrolled. In addition, b ased on emer ging data from Part 1, Group E may  not be 
enrolled in Part 2 (optional).
Part 2 (Optional):
Group D: subjects with normal renal function ( eGFR 
≥90mL/min/1.73m2)*
Group E: subjects with mild renal impairment (eGFR 60 to 89 mL /min/1.73m2)
Group F: subjects with ESRD on hemodialy sis 
*
If there are a sufficient number of subjects with normal renal function enrolled in Part 1 
(Group A) that match su bjects with renal impairment in other groups , a determination 
will be made regarding the enrollment of matching subjects with normal renal function in 
Part 2 (Group D ).
Subjects in Groups A, B, C, D, and Ewill enter the clinic at Check -in (Day -1, Period 1) 
before stud y drug administration (Day 1, Period 1). I n Parts 1 and 2, on Day 1 (Period 1),  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
10subjects in Group A, B, C, D, and E will receive a single dose of study  drug as follows: 
gepotidacin [ADDRESS_776221] been 
completed, and will return to the clinic for a Follow -up Visit approximately  10days 
(±5days) after dose administration. The duration of the study  (from Scre ening to the 
Follow -up V isit) will be approximately  44days. 
In Part 2 (optional) of the study , subjects in Group F will participate in [ADDRESS_776222] 7 day s. 
Subjects in Group F will enter the clinic at Check -in (Day  –1, Period 1 and Day  7, 
Period 2) before each study  drug administration (Day  1, Period 1 and Day  8, Period 2). 
On Day  1 (Period 1) and Day 8 (Period 2), subjects in Group F will receive a single dose 
of study  drug as follows: gepotidacin [ADDRESS_776223] hemodial ysis session of the 
week (Period 1) and gepotidacin [ADDRESS_776224] hemodialy sis session of the week (Period 2). 
Subjects in Group F will be discharged from the clinic on Day  10, Period [ADDRESS_776225] been completed, and will return to the clinic 
for a F ollow -up Visit approximately  10days (±5 days) after the last dose administration 
in Period 2. The duration of the study  (from Screening to the Follow -up Visit) will be 
approximately  50days.
Type and Number of Subjects
In Part 1, up to 16 subjects with no rmal renal function will be matched to approximately
8subjects with moderate renal impairment ,and approximately  
8 subjects with severe 
renal impairment and/or subjects with ESRD not on hemodialy sisfor a total of 
approximately  32subjects. I n Part 2 (optional) , approximately  4 to 8subjects with 
normal renal function (if enrolled), approximately  [ADDRESS_776226] on hemodialy sis will be 
enrolled for a total of approximately  12 
to 24subjects.
If there are a sufficient number of subjects with normal renal function enrolled in Part 1 
(Group A) that match subjects with renal impairment in other groups, a determination 
will be made regarding enrollment of matching subjects with normal renal function in 
Part 2 (Group D). In addition, if subjects prematurely  discontinue the study , additional 
replacement subjects may be enrolled at the discretion of the Sponsor in consultation with 
the investigator.
Analysis
Plasma and saliva concentrations of g
epotidacin will be anal yzed (as data permit) by  
[CONTACT_589348]: AUC from 
hour
[ADDRESS_776227] measurable plasma concentration (AUC(
0-t)), AUC extrapolated to 
infinity  (AUC (0-)), Cmax, time to maximum conce ntration (Tmax), apparent terminal 
phase half -life (t1/2) , systemic clearance (CL), volume of distribution at steady -state of 
parent drug (Vss; plasma only ), and volume of distribution of the terminal phase (Vz). 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
11Urine concentrations of gepotidacin will be analyzed (as data permit) by 
[CONTACT_589348]: total unchanged 
drug (Ae total), amount of drug excreted in urine (Ae (t1 -t2)), percentage of the given 
dose excreted in urine (fe %), and renal clearance (Clr ). 
Plasma , urine , and saliva (subjects in Part 1 only )concentrations of gepotidacin and the 
associated PK parameters will be listed, and summary  statistics (n, mean, median, 
standard deviation , minimum, maximum, and coefficient of variation ) will be presented 
by [CONTACT_589349]. Mean and individual plasma concentration versus time profiles will 
be presented graphically  on linear and semilogarithmic scales.
Dialy sate concentration of gepotidacin w ill be analy zed for all subjects with ESRD on 
dialy sis (Gr oup F subjects in Part 2 [optional] ) to determine the following PK metrics: 
total amount of unchanged amount of drug removed by [CONTACT_589350] (Arem) from time 0 
to 1 hour after the start of hemodialy sis (Arem (0-1) ), Arem from time 1 to 2 hours after 
the sta rt of hemodial ysis (Arem (
1-2)), Arem from time 2 to 3 hours after the start of 
hemodialy sis (Arem (
2-3)), Arem from time 3 to 4 hours after the start of hemodialy sis 
(Arem (3
-4)), cumulative amount of drug removed by  [CONTACT_589351] 0 to 4 
hours (or 
to the end of dialy sis if 
less tha n 4 hours; Arem(0-4)), partial area under the 
curve estimated from predialyzer samples collected from start of dial ysis (t0) to end of 
dialy sis (t1; AUC( t0-t1)), dialy sis clearance (CL D), and fraction (%) of the dose removed 
by [CONTACT_589352] 0 to 4 hours after the start of hemodialysis (or to the end of dial ysis 
if less than 4 hours; Frem% (
0-4)).Dialysate concentrations (Group F) of gepotidacin and 
the associated PK parameters will be listed, and summary  statistics (n, mean, median, 
standard deviation , minimum, maximum, and coefficient of variation ) will be presented 
by [CONTACT_589349].
Safety  endpoints will include monitoring adverse events, clinical laboratory  results, vital 
sign measurements [ADDRESS_776228] conventional 
and biothreat pathogens, including isolates resistant to existing classes of antimicrobials. 
Gepo tidacin selectively  inhibits bacterial DNA gyrase and topoisomerase IV by  a unique 
mechanism, which is not utilized by  [CONTACT_249221]. 
Structural data with a t ype II topoisomerase, DNA gyrase, reveals the novel binding 
mode of the class and distinguishes it from the binding mode of the quinolone 
antibacterials [ Bax, 2010]. As a consequence of its novel mode of action, gepotidacin is 
active in vitro against target pathogens carry ing resistan ce determinants to established 
antibacterials, including fluoroquinolones.
2.1. Stud y Rationale
In a previous absorption, distribution, metabolism, and excretion study  for gepotidacin 
(See [COMPANY_004] Document Number 2014N189951_00 Study  ID Study  BTZ115774), the mean 
recovery  of radioactivit y in urine accounted for approximately  60% of [14C]-gepotidacin 
administered as a single IV dose. In addition, renal clearance of gepotidacin has been 
estimated to be approximately  40% of total s ystemic drug clearance. Therefore, renal 
impairment has the potential to adversel y affect the elimination of gepotidacin.
It is expected that potential patients in future gepotidacin Phase III studies may  have at 
least some degree of renal impairmen t. The results from this study  will enable the 
development of appropriate dosing recommendations in patients with impaired renal 
function.
2.2. Brief Background
Gepotidacin has demonstrated clinical efficacy  in a Phase IIstudy  for acute bacterial skin 
and skin structure infections, and is currentl y being evaluated in a Phase IIstudy  for 
gonorrhea. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
133. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary
To compare the pharmacokinetics of 
gepotidacin administered as a 750 -mg 
IV dose in normal healthy subjects 
compared with subjects with mild, 
moderate, and severe renal 
impairment, and with subjects with 
end-stage renal disease (ESRD)Plasma primary pharmacokinetic (PK) endpoints 
include AUC(0- ∞) and Cmax of gepotidacin, as 
data permit
Urine primary PK end points include Ae total, 
fe%, and CLr of gepotidacin, as data permit
Dialysate primary PK end points include 
AUC(t0 -t1), CL D, and Frem%(0 -4), of 
gepotidacin, as data permit
Secondary
To assess the safety and tolerability of 
gepotidacin administered as a [ADDRESS_776229]12-lead safety electrocardiogram readings, 
change from baseline in vital sign 
measurements (blood pressure and heart rate), 
monitoring of adverse events, toxicity grading of 
clinical laboratory test results, and physical 
examinations
To evaluate the secon dary PK 
parameters of gepotidacin
administered as a [ADDRESS_776230]Plasma PK endpoints include AUC(0- t), CL, z, 
t1/2, Tmax, Vss , and Vz, as data permit
Urine PK endpoint includes Ae(t1 -t2), as data 
permit
Dialysate PK endpoints include Arem(0 -1), 
Arem(1 -2), Arem(2 -3), Arem(3 -4), and 
Arem(0 -4), as data permit
Exploratory
To evaluate the saliva 
pharmacokinetics of gepotidacin 
(subjects in Part 1 only)Primary PK endpoints include AUC(0 -∞) and 
Cmax of gepotidacin, as data permit
Secondary PK endpoints include AUC(0 -t), CL, 
λz, t1/2, Tmax, Vss, and Vz, as data permit
ESRD = end -stage renal disease; PK = pharmacokinetic
4. STUDY DESIGN
4.1. Overall Design
This is a Phase I, nonrandomized, open- label, parallel -group, multi -center, multi -part 
study  that will evaluate the pharmacokinetics, safety , and tolerability  of a single IV dose 
of gepotidacin 750 mg over 2 hours in subjects with normal renal function; subjects with 
mild, moderate, and severe renal impairment; and subjects with end -stage renal disease 
(ESRD; on dialy sis and not on dialy sis). Subjects with renal impairment will be matched 
to subjects with normal renal function in terms of g ender distribution, age (approximately  
±10 y ears), and body  mass index (BMI ; approximately  ±20%) .
At Screening, subjects will be enrolled to the appropriate groups based on the 
classification as defined in the Food and Drug Administration ( FDA )draft guida nce for  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
14industry , “Pharmacokinetics in Patients with I mpaired Renal Function – Study  Design, 
Data Anal ysis, and Impact on Dosing and Labeling” [ DHHS , 2010]. Subjects with 
normal renal function and subjects with renal im pairment will be classified based on the 
estimated glomerular filtration rate (eGFR; based on the Modification of Diet in Renal 
Disease Study ). Subjects with normal renal function will also be classified based on 
estimated creatinine clearance (Clcr). For more details see Section 6.2.
This will be a multi -part study , in which pharmacokinetic (PK) requirements must be met 
(observed mean values: area under the curve [ AUC ]<48 ghr/mL and maximum 
observed concentra tion [ Cmax ]<14 g/mL); and safety and tolerability will be reviewed 
before enrolling subjects into the next part of the study . In Part 1, subjects with normal 
renal function; subjects with moderate renal impairment; and subjects with severe renal 
impairme nt and subjects with ESRD not on hemodialy sis will be enrolled. In Part 2 
(optional), subjects with normal renal function, subjects with mild renal impairment, and 
subjects with ESRD on hemodialy sis will be enrolled based on the PK, safety , and 
tolerability data of Part 1.  Subjects with mild renal impairment may  be studied if there is 
a significant difference in PK between subjects with moderate and severe renal 
impairment compared to subjects with normal renal function and modelling cannot 
accuratel y pred ict PK in subjects with mild renal impairment.  Subjects with ESRD on 
hemodialy sis will be studied provided that the PK requirements are met ( observed mean 
values in 
subjects with severe impairment do not exceed the threshold: area under the 
curve [AUC] <48 ghr/mL  and maximum observed concentration [Cmax] <14 
g/mL).  
Thedose may  be adjusted for subjects with ESRD on hemodialy sisif either PK 
param eter is predicted to exceed the threshold.  See the study  schematic in Figure 1for 
more details.
For subjects with normal renal function , subjects with mild, moderate, and severe renal 
impairment ,and subjects with ESRD not on dialy sis: subjects will participate in 
1treatment period and blood and urine 
samples will be collected for PK analy sis of 
gepotidacin concentrations according to the Time and Events T ables ( Table 2and Table 
3). In addition, saliva samples (subjects in Part 1 only)will be collected for the 
PKanaly sis of gepotidacin concentrations according to the Time and Events Tables 
(Table 2 and Table 3).Blood , urine, and saliva samples will be
collected up to 
approximately  [ADDRESS_776231] on hemodialy sis: subjects will participate in 2 treatment periods 
and b
lood and urine (if applicable ) samples in Period 1 will be collected for PK anal ysis 
of gepotidacin concentr ations according to the 
Time and Events Tables ( Table 4and 
Table 5). Blood and urine (if applicable) samples will be collected up to approximately  
48hours after dosing (i .e.,the last sample will be collected before the next hemodialy sis 
session
). In addition, dialysate samples will be collected for the determination of 
gepotidacin concentrations according to the Time and Events Tables ( Table 4and Table 
5).
Optional PKAssessment: with the subject’s consent, if a kidney  or bladder tissue 
sample 
is collected for a nonstudy purpose during this study , excess tissue may  be collected and 
used fo r the purposes of measuring tissue gepotidacin concentrations . 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
15Figure [ADDRESS_776232] = end -stage renal disease ; PK = pharmacokinetic
a If there are a sufficient number of subjects with normal renal function enrolled in Part 1 (Group A), a determination 
will be made regarding enrollment of matching subjects with normal renal function in Part 2 (Group D).
b Based on emerging data from Part 1, Group E (subjects with mild renal impairment) may not be enrolled in Part 2 
if there is not a significant difference between subjects with moderate and severe impairment compared to 
subjects with normal renal function or if the PK can be accurately predicted.    
c If AUC and/or Cmax is predicted to e xceed the threshold, the dose may be adjusted in Group F (optional). 
4.2. Treatment A rms and Duration
Subjects will be screened within 30 day s prior to entry  to the clinic and will be enrolled 
as follows:
Part 1:
Group A: subjects with normal renal function (eGFR ≥90 mL/min/1.73m2)
Group B: subjects with moderate renal impairment (eGFR 30 to 59 mL/min/1.73m2)
Group C: subjects with severe renal impairment and subjects with ESRD not on 
hemodialy sis (eGFR <30 mL/min/1.73m2)
If PK, safet y, and tolerability  requir ements are not met in Part 1, and based on the 
emerging data, and/or data that are not expected to exceed the requirements in the 
subjects with ESRD on hemodialy sisor may  require dose adjustment , subjects for Part 2 
will be enrolled. In addition, b ased on emerging data from Part 1, Group E may  not be 
enrolled in Part 2 (optional).Part 1
Group A: Subjects with normal renal function
Group B: Subjects with moderate renal impairment
Group C : Subjects with severe renal impairment and subjects 
with ESRD not on hemodialysis
PK requirements to continue to Part 2
Observed Mean Values:
AUC <48 ghr/mL
Cmax <14 g/mL
(Based on emerging data, and/or data that are not expected to 
exceed these requirements in subjects with ESRD on 
hemodialysis or may require dose adjustment, subjects in Part 
2 will be enrolled.)
Part 2 (Optional)
Group D : Subjects with normal renal functiona
Group E: Subjects with mil d renal impairmentb
Group F : Subjects with ESRD on hemodialysisc 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
16Part 2 (Optional):
Group D: subjects with normal renal function ( eGFR ≥90 mL/min/1.73m2)*
Group E: subjects with mild renal impairment (eGFR 60 to 89 mL /min/1.73m2)
Group F: subjects with ESRD on hemodialy sis 
* If there are a sufficient number of subjects with normal renal function enrolled in Part 1 
(Group A) that match su bjects with renal impairment in other groups, a determination 
will be made regarding the enrollment of matching subjects with normal renal function in 
Part 2 (Group D).
Subjects with renal impairment will be matched to subjects with normal renal function i n 
terms of gender distribution, age (approximately  ±10 y ears), and BM I (approximately  
±20%).
Subjects in Groups A, B, C, D (if enrolled; see Section 4.3for more details) , and E will 
enter the clinic at Check -in(Day  –1,Period 1) before study  drug administration (Day  1,
Period 1). On Day 1 (Period 1), subjects in Group A, B, C, D, and Ewill receive a single 
dose of study  drug as follows: gepotidacin [ADDRESS_776233] been completed, and will return to the clinic for a Follow -up Visit 
approximately  10days (±5days) after dose administration. The duration of the study  
(from Screening to the Follow -up V isit) will be approximately  44days. 
In Part 2 (optional) of the study , subjects in Group F will participate in [ADDRESS_776234] 7 day s. 
Subjects in Group F w ill enter the clinic at Check- in (Day  –1, Period 1 and Day  7, 
Period 2) before each study  drug administration (Day  1, Period 1 and Day  8, Period 2). 
On Day  1 (Period 1) and Day 8 (Period 2), subjects in Group F will receive a single dose 
of study  drug as f ollows: gepotidacin [ADDRESS_776235] hemodial ysis session of the 
week (Period 1) and gepotidacin [ADDRESS_776236] hemodialy sis session of the week (Period 2). 
Subjects in Group F will be discharged from the clinic on Day  [ADDRESS_776237] been completed, and will return to the clinic 
for a F ollow -up Visit approximately  10days (±5 days) after the last dose administration 
in Period 2. The duration of the study  (from Screening to the Follow -up Visit) will be 
approximately  50days.
4.3. Type and Number of Subjects
In Part 1, up to 16 subjects with no rmal renal function will be matched to approximately  
8subjects with moderate renal impairment, and approximately  8 subjects with severe 
renal impairment and/or subjects with ESRD not on hemodialysis for a total of 
approximately  32subjects. I n Part 2 (opt ional), approximately  4 to 8 subjects with 
normal renal function (if enrolled), approximately  [ADDRESS_776238] on hemodialy sis will be 
enrolled for a total of approximately  12 to 24 subjects. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
17If there are a sufficient number of subjects with normal renal function enrolled in Part 1 
(Group A) that match subjects with renal impairment in other groups, a determination 
will be made regarding enrollment of matching subjects with normal renal function in 
Part 2 (Group D). In addition, i f subjects prematurely  discontinue the study , additional 
replacement subjects may  be enrolled at the discretion of the Sponsor in consultation with 
the investigator.
4.4. Design Justification
This study  design is comm only used when evaluating the pharmacokinetics of a drug 
entity  in subjects with impaired renal function. It is based on recommendations given in 
the FDA draft guidance for industry , Pharmacokinetics in Patients with I mpaired Renal 
Function — Study  Design, Data Anal ysis, and Impact on Dosing and Labeling 
[DHHS ,2010]. 
Gepotidacin exhibits linear and time -independent pharmacokinetics, which indicates a 
single -dose study  is adequate to achi eve study  objectives. A multiple -dose study  is not 
necessary  since there are no safet y concerns with metabolites of this study  drug.
4.5. Dose Justification
The proposed single IV infusion dose of gepotidacin [ADDRESS_776239] single IV dose of gepotidacin (1800 mg) evaluated in adult health y subjects.
A physiologicall y-based pharmacokinetic (PBPK) model was developed for gepotidacin 
using the SimCYP population based absorption, distribution, metabolism, and excretion 
(ADME) simulator Version 15 (Certara [LOCATION_003], Inc, Princeton, NJ). Pharmacokinetic data 
from health y Caucasian subjects following single 2 -hour IV infusion doses of 400 mg, 
1000 mg, and 1800 mg (see [COMPANY_004] Document Number 2014N198291_00 Study  ID 
BTZ115198) was used to predict the intrinsic hepatic clearance. The predictive 
performance of the PBPK model was verified b y comparing the observed AUC from time 
[ADDRESS_776240] quantifiable concentration ( AUC(0 -t)) and Cmax of gepotidacin 
to the predicted values at the 3 doses of 400 mg, 1000 mg, and 1800 mg . This model was 
further validated using a 750- mg IV 2-hour infusion dosing regimen in Japanese subjects 
from the same clinical study  [see report of Stud y BTZ115198 ]. The model predictions 
agreed well with the observed data for the Caucasian population for all 3 dosing 
regimens , with predicted and observed values of a 5% to 12% difference in AUC(0 -t) and 
a 1% to 5% difference, respectively , in Cmax. Simulations were also in good agreement 
with PK data in Japanese subjects. The model input parameters are listed in Appendix 11.
The PBPK model was then utilized to predic t exposure for the proposed dosing regimen 
(750-mg IV 2-hour infusion) in healthy  Caucasian subjects with normal renal function 
and subjects with various levels of impaired renal function as implemented in SimCYP 
with a female to male ratio of 0.5. The sim ulations were performed with the assumption 
of only  GFR changes in subjects with renal impairment (software “RenalGFR30-60” and 
“RenalGFR_less_30 ”) and no active renal secretion due to the limited understanding of 
renal uptake mechanism for gepotidacin. Th e predicted geometric mean in gepotidacin 
exposure (AUC(0- t)) for subjects with moderate and severe renal impairment was  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
18increased up to 2.0 -fold compared with health y subjects with normal renal function 
(Table 1).
Table 1 Simulated Gepotidacin Pharmacokinetic Parameters in Healthy  
(Normal) and Renally  Impaired Populations
Pharmacokinetic
ParametersPredicted Geomean (CV%) [N = 100]
Healthy 
(Normal Renal Function )
(GFR ≥90 mL/min)Moderate Renal 
Impair ment
(GFR 30 to 60 mL/min)Severe Renal Impair ment
(GFR 15 to <30 mL/min)
Cmax ( g/mL) 5.65 (18) 7.29 (19) 7.93 (20)
AUC(0 -t) (gh/mL) 17.5 (23) 25.8 (24) 28.9 (26)
CV = coefficient of variation; GFR = glomular fil tration rate; N = number of subjects included in thesimulation
4.6. Benefit: Risk Assessment
Summaries of findings from both clinical and nonclinical studies conducted with 
gepotidacin can be found in the Investigator’s Brochure (IB).The following section 
outlines the risk assessment and mitigation strategy for this protocol . 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
194.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) Gepotidacin
Gastrointestinal (GI) Effects Lower GI effects (soft stools, flatulence, and diarrhoea) are 
the most common GI -associated adverse events ( AEs)
reported in human subjects dosed with gepotidacin.
In the Phase I studies, out of approximately [ADDRESS_776241] received gepotida cin, C. difficile has 
been reported in 8 subjects.Exclusion criterion and close monitoring of clinical 
parameters and AEs will be conducted to mitigate and 
assess GI effects.
Patients with significant GI symptoms will obtain the 
appropriate work -up (Appendix 8).
Subject stoppi[INVESTIGATOR_3418]: Subjects experiencing Grade [ADDRESS_776242] permanent discontinuation of the 
investigational medication and will be followed as 
appropriate until resolution of the AE.
Cardiovascular Effects
Reversible increase in QT prolongation and a mild 
increase in heart rate in human subjects.In Study BTZ115775 [see GlaxoSmithKline Document 
Number 2015N227098_00 Study ID BTZ115775] , the 
infusion of gepotidacin at a dose of [ADDRESS_776243] of 
approximately 6 bpm to 10 bpm and a QTprolongation, 
measured as ∆∆QTcF, of 12 msec to 22 msec. The 
QTprolongation evolved during the infusion and was 
quickly reversed over 2 hours after the end of the infusion.
Blood pressure observations were within normal ranges. Exclusion criteria, close monitoring of clinical parameters, 
and AEs will be conducted and stoppi[INVESTIGATOR_589331] a nd assess cardiovascular effects.
Note: Subjects with a QRS duration <70 and >[ADDRESS_776244] stoppi[INVESTIGATOR_3418]: Subjects experiencing a QTcB 
and/or QTcF >500 msec and/or a change from baseline in 
QTc >60 msec.
Acetylcholinesterase ( AChE) Inhibition
In a mass spectrometry model performed with gepotidacin, 
AChE was inhibited with a concentration of inhibitor where 
the response (or binding) wasreduced by [CONTACT_2016] (inhibitory 
concentration) of approximately 5 µg/mL (7.5 µg/mL of 
total drug concentration).At higher doses, some subjects have experienced effects 
consistent with increased cholinergic tone, including 
central nervous system and GI effects ( increased 
salivation, slurred speech, blurred vision, dizziness, 
light-headedness, and GI upset) . These effects appear to 
be related to Cmax and are significantly attenuated when 
Cmax is below 14 g/mL.Coadministration of anticholinergics and administration in 
subjects with certain concomitant conditions will be 
excluded.
Close monitoring of clinical parameters and AEs will be 
conducted to assess effects potentially related to AChE
inhibition. The Cmax will be below 14 g/mL in this study. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
20Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Infusion -Site Reactions Infusion -site reactions (mild to moderate), including 
phlebothrombosis, have bee n observed more frequently 
following repeat dosing at higher doses ( 750 mg BID).
Infusion -site reaction events were reported as AE sfor 2 of 
122 subjects (2%) and consisted of mild, related 
infusion -site pain (see [COMPANY_004] Document Number 
2015N243789_00 Study ID BTZ116704) . Intravenous administration of gepotidacin is given by a 
slow infusion following carefully defined procedures to 
minimize risk of infusion site reactions.
Infusion -site reactions will be evaluat ed in an ongoing 
fashion throughout the study with interventions 
implemented as appropriate.
Rash/Hypersensitivity A fine, mild, generalized pruritic macular skin rash was 
seen in 3 of 8 subjects following 10 days of dosing 
1500 mg 3 times daily ( see the report of Study 
BTZ115198 ).
Rash was reported as an AE for 4 of 122 subjects (3%) 
and consisted of mild, related urticaria; moderate, related 
rash maculopapular; mild, related rash; mild, related 
urticaria; and mild, n ot related arthropod bite ( seereport of
Study ID BTZ116704 ).
There has been no other evidence of hypersensitivity in 
human subjects to date.Exclusion criterion :
History of sensitivity to any of the study drugs, componen ts 
thereof, or a history of drug or other allergy that, in the 
opi[INVESTIGATOR_249194], contraindicates their participation.
Subject monitoring:
Patients will be monitored closely for cutaneous effects 
throughout the study, and specialist advice will be sought 
as needed to evaluate any clinically significant finding.
Subject stoppi[INVESTIGATOR_3418] :
Grade 3 or higher rash or Grade 2 rash with evidence of 
systemic involvement. 
 
 2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
214.6.2. Benefit A ssessment
Since this Phase I study  is being conducted in healthy  subjects with normal renal 
function; in subjects with mild, moderate, and severe renal impairment; and insubjects 
with ESRD (on and not on hemodialy sis), there is no direct clinical benefit to study  
subjects. Participation in this study  will contribute to the process of developi[INVESTIGATOR_589332].
4.6.3. Overall Benefit:Risk Conclusion
The risk of adverse events ( AEs)
is minimized for the populations being investigated in 
the proposed stud y by [CONTACT_589353] y; the relativel y 
short duration of study  drug exposure; and the extent of safet y monitoring incorporated 
into the study .
5. SELECTION OF STUDY POPULA TION AND WITHDRA WAL 
CRITERIA
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on the [COMPANY_004] investigational product or other stud y treatment that 
may impact subject eligibility  is provided in the IB.
Deviations from inclusion and exclusion criteria are not allowed because they  can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability ,or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
A subject will be eligib le for inclusion in this study  only  if all of the following criteria 
apply :
AGE
1. M ale or female subject between [ADDRESS_776245] be in clinically  stable hea lth as determined by  [CONTACT_589354] , clinical laboratory  results (serum chemistry , hematology , 
urinaly sis, and serology ), vital sign measurements, 12 -lead electrocardiogram (ECG) 
results, and ph ysical examination findings. Subjec t with renal impairment must have 
clinical laboratory  values consistent with their disease and are approved b y the 
investigator.
3. S ubject with renal impairment (mild, moderate, severe, or subjects with ESRD) may  
be taking medications, which in the opi[INVESTIGATOR_1649] o f the investigator, are believed to be 
therapeutic but do not affect study drug absorption, distribution, metabolism, or 
excretion. These medications must be stable doses taken for at least 7days before the 
first dose of study  drug. Any exceptions will be discussed with the sponsor or medical  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
22monitor on a case -by-case basis and the reasons documented.
4.Subject with normal renal function or renal impairment (estimated eGFR 
corresponding to the calculated eGFR [ the estimated eGFR may  be rounded to the 
nearest integer ])at Screening (Section 6.2).
5.Subjects with ESRD on hemodialysis should be on hemodialy sis for at least 3 months 
before Screening and is able to tolerate a hemodialy sis treatment lasting 3 to 4 hours 
with blood flow rates of >200 mL /min.
6. Alanine aminotransferase (ALT) and bilirubin <1.5 × upper limit of normal (ULN; 
isolated bilirubin >1.5 × ULN is acceptable ,if bilirubin is fractionated and direct 
bilirubin <35%).
WEI GHT
7.Body weight 50 kg and BMI within the range 18.5 and 40 kg/m2, inclusive.
SEX
8.Male or Female
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative serum human chorionic gonadotrophin test), not lactating, and at least one of the 
following c onditions applies:
aNonreproductive potential defined as:
Premenopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented bilateral oophorectom y
Postmenopausal defined as 12 months of continuous spontaneous amenorrhea (in 
questionable cases a blood sample will be obtained to test for simultaneous 
follicle -stimulating hormone and estradiol levels consistent with men opause (refer 
to laboratory  reference ranges for confirmatory  levels). Females on hormone 
replacement therap y (HRT) and whose menopausal status is in doubt will be 
required to use one of the highl y effective contraception methods if they wish to 
continue t heir HRT during the stud y. Otherwise, they must discontinue HRT to 
allow confirmation of post- menopausal status prior to study  enrol lment.
b Reproductive potential and agrees to follow [ADDRESS_776246] ive Methods for Avoiding Pregnancy  in Fem ales of 
Reproductive Potential (Appendix 7) requirements from [ADDRESS_776247] be documented by  [CONTACT_132067] (subjects with ESRD only ).
The investigator is responsible for ensuring that subjects understand how to properl y use  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
23methods of contraception. 
INFORMED CONSENT
9. Capable of giving signed informed consent as described in Section 10.2, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in thi s protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.Subject has a clinicall y significant abnor malit y in past medical history or at the 
Screening ph ysical examination (excluding renal insufficiency  and other related 
stable medical conditions within the renally  impaired population of subjects 
[e.g.,hypertension, diabetes, or anemia, which should be stable for at least [ADDRESS_776248] dose of study  drug]) that in the investigator’s opi[INVESTIGATOR_589333] . This includes, but is 
not limited to, history  or current cardiac, hepatic, neurologic, gastrointestinal (GI), 
respi[INVESTIGATOR_696] , hematologic, or immunologic disease.
2.Subject has an y surgical or medical condition (active or chronic) that may interfere 
with drug absorption, distribution, metabolism, or excretion of the study  drug, or an y 
other condition that may  place the subject at risk , in the opi[INVESTIGATOR_871] .
3.Subject has a functioning renal transplant.
4. Subject with renal impairment has a s ystolic blood pressure outside the range of [ADDRESS_776249] with renal impairment has a hemoglobin value < 9 g/dL .
6.Female subject has a positive pregnancy  test result or is lactating at Screening or upon 
admission to the clinic .
7.Use of a systemic antibiotic within [ADDRESS_776250] ugand/or alcohol abuse within [ADDRESS_776251] has a positive drug screen at Screening 
or upon admission to the clinic . For subjects with renal impairment , a positive drug 
screen result related to the use of prescription medications is allowed per investigator 
review and approval ,andtetrah ydrocannabinol use is allowed per investigator review 
and approval.
10.History  of sensitivity  to any  of the stud y drugs ,
components thereof, or a history  of 
drug or o ther allergy  that, in the opi[INVESTIGATOR_249200] , 
contraindicates their participation.
11.History  of sensitivity  to heparin or heparin -induced thrombocy topenia (if the clinic  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
24uses heparin to maintain IV cannula patency ).
CONCOMI TANT MEDICATIONS
12.Subject has used medications known to affect the elimination of serum creatinine 
(e.g., trimethoprim or cimetidine) or competitors of renal tubular secretion 
(e.g.,probenecid) within 30 days before dosing.
13. S ubjects cannot use an y over-the-counter, or prescription medication (except for 
hormonal contraceptives and/or acetaminophen ; see Section 
6.11 for more details ), 
vitamin supplement, or herbal medication within 7 days (or 5 half-lives, whichev er is 
longer) before dosing and during the stud ywithin 7 day s before dosing and during the 
study . 
Any exceptions (including subjects with renal impairment that will be on 
medications during the study ) will be discussed with the sponsor or medical monitor 
on a case -by-case basis and the reasons will be documented.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
14.Subjects with normal renal function have a presence of hepatitis B surface antigen or
positive hepatitis C antibody test result at Screening or within [ADDRESS_776252] ha s clinically  significant abnormal findings in serum chemistry , hematology , 
or urinal ysis results obtained at Screening or Day –1(and Day 7 for Group F only), 
other than those associated with underl ying renal conditions or other stable medical 
conditions c onsistent with the disease process.
17. Subject with normal renal function has a baseline corrected QT interval using the 
Fridericia formula (QTcF) of >450 milliseconds (msec) and subject with renal 
impairment has a baseline QTcF of>[ADDRESS_776253] dosing day  in the current 
study : [ADDRESS_776254] (whichever is longer).
21. Subject is unable to comply  with all study  procedures, in the opi[INVESTIGATOR_1070].
22.The s ubject should not participate in the stud y, in the opi[INVESTIGATOR_871] o r 
Sponsor . 2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
255.3. Screen ing/Baseline /Run-in Failures
Screen failures are defined as subjects who consent to participate in the clinical trial but 
are never subsequently  dosed . In order to ensure transparent reporting of screen failure 
subjects, meet the Consolidated Standards of Reporting Trials publishing requirements, 
and respond to queries from r egulatory  authorities, a minimal set of screen failure 
information is required including demography , screen failure details, eligibility  criteria, 
and serious adverse events (SAEs) .
5.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the clinic 
for a required stud y visit:
The clinic must attempt to contact [CONTACT_589355]. 
The clinic must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed “lost to follow -up”, the investigator or designee 
must make every  effort to regain contact [CONTACT_1155] (where possible, 
3 telephone calls , emails, or text messages; and,if necessary , a certified letter to the 
subject’s last known mailing address or local equivalent methods) . These contact 
[CONTACT_9300]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered to 
have withdrawn from the study  with a primary  reason of “ lost to follow -
up.” 
A subject may withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral ,or 
administrative reasons. If a subject withdraws from the study , he/she may  request 
destructio n of an y samples taken, and the investigator must document this in the clinic 
study  records . 
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology in alignment with the FDA
guidance, “Drug -Induced L iver Injury : Premarketing Clinical Evaluation ,”
[DHHS , 2009]. 
Study  treatment will be stopped if the following liver chemistry stoppi[INVESTIGATOR_196140]: 
ALT3 ×ULN
Although stoppi[INVESTIGATOR_589334] -dose studies, and, in this case, for 
subjects that will receive the gepotidacin dose twice (Group F), 
if subjects are found to 
have values consistent with usual stoppi[INVESTIGATOR_128007], it is appropriate to institute 
evaluation and monitoring criteria according to standard [COMPANY_004] criteria. Therefore, liver  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
26function tests should be evaluated according to stoppi[INVESTIGATOR_589335]- up instituted if 
defined parameters are reached.
For details of the required assessments if a subject meets the above criteria , refer to 
Appendix 2, Liver Chemistry Follow -up Procedures.
5.4.2. QTc Stoppi[INVESTIGATOR_42168]
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study . This formula may  not be 
changed or substituted once the subject has been enrolled.
For example, if a subject is eli gible for the protocol based on thecorrected QT 
interval using the Fridericia formula, then 
the corrected QT interval using the 
Fridericia formula must be used for discontinuation of this individual subject as 
well.
Once the QT correction formula has been chosen for a subject’s eligibility , the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis . Safety  ECGs and other nonprotocol specified ECGs 
are an exception.
The QTc should be based on single or averaged QTc values of triplicate ECGs 
obtained over a brief (e.g., 5 to 10 minute) recording period.
A subject who meets either of the bulleted criterion below will be withdrawn from the 
study :
QTcF >500 msec
Change from baseline of QTc >60 msec
For patients with underl ying bundle branch block , follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle Branch Block Discontinuation QTc with Bundle Branch Block
<450 msec >500 msec
450 to480 msec ≥530 msec
5.4.3. Gastrointestinal Stoppi[INVESTIGATOR_589336] 3 or Grade 4 AEs (confluent pseudomembranes or 
ulcerations OR mucosal bleeding with minor trauma; tissue necrosis OR diffuse 
spontaneous mucosal bleeding OR life -threatening consequ ences, e.g., aspi[INVESTIGATOR_1516], 
choking) will be followed as appropriate until resolution of the AE (s).
Furthermore , subjects who experience diarrhoea or enteritis should be evaluated with 
additional fecal occult blood tests and stool cultures as deemed appropria te by  [CONTACT_249227] 8andAppend ix 9. 2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
275.4.4. Rash/Hy persensitivity Stoppi[INVESTIGATOR_2121]
A subject presenting with a Grade 3 AEor higher rash (diffuse macular, mac ulopapular, 
ORmorbilliform rash with vesicles or limited number of bullae ;OR s uperficial 
ulcerations of mucous membrane limited to 1 site) or a Grade 2 rash (diffuse macular, 
maculopapular, or morbilliform rash ;OR t arget lesions )with evidence of s ystem ic 
involvement will be followed as appropriate until resolution of the AE(s).
5.5. Subject and Study  Completion
A completed subject is one who has completed all phases of the stud y including the 
Follow -up V isit.
The end of the stud y is defined as the last subje ct’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term “study  treatment” is used throughout the protocol to describe any  combination 
of products received b y the subject as per the protocol design. Stud y treatment may ,
therefore ,refer to the individual study  treatments or the combination of those study  
treatments.
Study Treatment
Product name: [CONTACT_589366] ( [COMPANY_004]2140944 )
Dosage form: IV
Unit dose strength/Dosage level: 750 mg
Route of Administration/Duration Single IV dose over 2 hours
Dosing instructions: Instructions for the preparation of the IV drug are 
included in the Study Procedures Manual.
Physical description: Gepotidacin lyophile is a pale yellow to greyish 
yellow cake.
Reconstituted solution: A clear, dark brown to dark 
brownish -yellow solution after reconstitution, free 
from visible particulate matter.
Manufacturer/Source of procurement: GlaxoSmithKline
6.2. Treatment A ssignment
This is anonrandomized, open -label stud y. Clinic personnel will enroll the subj ect into 
the study  once a subject has met all eligibility  requirements.
At Screening, subjects will be enrolled to the appropriate groups based on the 
classification as defined in the FDA draft guidance for industry , “Pharmacokinetics in 
Patients with I mpaired Renal Function –Study  Design, Data Anal ysis, and Impact on 
Dosing and Labeling” [DHHS , 2010].  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
28Subjects with normal renal function and subjects with renal impairment (or ESRD) will 
be assigned to a stud y group bas ed on their eGFR calculated using the isotope dilution 
mass spectrometry -traceable Modification of Diet in Renal Disease formula as follows:
eGFR (mL/min/1.73 m2) = 175 × (serum creatinine) –1.154 × (age) – 0.203 × 
(0.742if female) × (1.212 if African Am erican)
In addition, subjects with normal renal function will be classified based on estimated Clcr 
by [CONTACT_16424] -Gault equation.
CLcr in mL/min is estimated from a spot serum creatinine (mg/dL) determination using 
the following formula: 
Clcr (mL /min) = [140 − age (y ears)] × weight (kg) ÷ 72 × serum creatinine (mg/dL) 
(×0.85 for female patients)
Subjects will be given a subject number that will be a unique identifier. Once a subject 
number has been assigned, the number will not be reused even if the su bject withdraws 
from the study  before receiving gepotidacin .
6.3. Planned Dose A djustments
Planned d ose adjustments are not allowed during this study .However, based on emerging 
data from Part 1 (or Period 1 for Group F), the Part 2 (or Period 2 for Group F ) dose may  
be reduced.
6.4. Blinding
This will be an open -label study . 
6.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.6. Preparation/Handling/Storage/A ccountability
A description of the methods and 
materials required for the preparation of gepotidacin
will be detailed in a Study Specifi c Technical Agreement/Memo or pharmacy  manual 
which will be accompanied by  a Qualit y Agreement .
The investigator or designee must confirm appropriate temperature condi tions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are to be reported and resolved before use of the study  treatment.
Only  subjects enrolled in the study  may  receive study  treatment and onl y authorized 
clinic staff may  suppl y or administer study treatment. All study  treatments must be 
stored in a secure environmentally  controlled and monitored (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the 
investigator an d authorized clinic staff.  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
29The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (i.e. ,receipt, reconciliation ,and final disposi tion records).
Further guidance and information for final disposition of unused study  treatment are 
provided in the Study  Reference Manual ( SRM ).
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant sa fety risks to clinic staff.
A Material Safety  Data Sheet or equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon req uest from 
[COMPANY_004].
6.7. Compliance with Study  Treatment A dministration
When subjects are dosed at the clinic , they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents. The dose of study  
treatment and study subject identification will be confirmed at the time of dosing b y a 
member of the clinic staff other than the person administering the study  treatment.
Gepotidacin willbe administered IV to subjects at the clinic . Administration will be 
documented in the source documents and reported in the electronic case report form 
(eCRF ).
6.8. Treatment of Study  Treatment Overdose
Gepotidacin will be administered at the clinic , thus limiting the risk of overdose. In the 
unlikely  event that an overdose with gepotidacin should occur, the investigator must 
notify  the sponsor promptly . There is no specific antidote for overdose with a bacterial 
topoisomerase inhibitor such as gepotidacin . In the event of a suspected overdose, it is 
recommended that the appropriate supportive clinical care should be instituted, as 
dictated by [CONTACT_423]’s clinical status.
[COMPANY_004] does not recommend specific treatment for an overdose.
In the event of an overdose the investigator should:
1.
Contact [CONTACT_10990]
2.Closely  monitor the subject for AEs/SAEs and laboratory  abnormalities until 
gepotidacin can no longer be detected s ystemically  (at least 3days for gepotidacin )
3. O btain a plasma sample for 
PK a nalysis within 3days from the date of the last dose 
of study  treatment if requested by  [CONTACT_7195] (determined on a case -by-case 
basis)
4. D ocument the quantit y of the excess dose as well as the duration of the overdosing in 
the eCRF 2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
30Decisions regarding dose interruptions or modifications will be made by  [CONTACT_589356] a clinical evaluation of the subject.
6.9. Treatment after the End of the Study
Subjects will not receive any additional treatment from GS K after completion of the 
study  because onl y healthy subjects; subjects with mild, moderate, and severe renal 
impairment ; and subjects with ESRD are eligible for study  participation.
The investigator is responsible for ensuring that consideration has been given to the 
post-study  care of the subject’s medical condition, whether or not [COMPANY_004] is providing 
specific post -study  treatment.
6.10. Lifest yle and/or Dietary  Restrictions
6.10.1. Meals and Dietary  Restrictions
Standard meals will be provided during the stud y dosing per iod at specified times.
Subjects will r efrain from consumption of red wine, Seville oranges, grapefruit or 
grapefruit juice ,pummelos, pomegranate juice ,exotic citrus fruits, grapefruit hy brids ,or 
fruit juices from [ADDRESS_776255] dose of study medication until after the final 
dose.
6.10.2. Caffeine andAlcohol
Subjects will abstain from ingesting caffeine -or xanthine -containing products (e.g., 
coffee, tea, cola drinks ,and chocolate) for 24
hours prior to the start of dosing until 
collection of the final PK sample. 
During each dosing session, subjects will abstain from alcohol for 24 hours prior to 
the start of dosing until collection of the final PK sample. 
6.10.3. Activity
Subjects will abstain from strenuous exercise for 48 hours prior to each blood colle ction 
for clinical laboratory  tests. Subjects may  participate in light recreational activities during 
the stud y(e.g., watch television, read).
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014]
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_589337], a cetaminophen at doses of ≤2 grams/day  is 
permitted ; and in subjects with renal impairment or ESRD, acetaminophen at doses of 
≤
2grams/day  is permitted for use with the approval of the investigator . Other 
concomitant medication may  be c onsidered on a case -by-case basis by  [CONTACT_67633]. 2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
31Subjects with renal impairment and subjects with ESRD may  be taking medication sthat 
areconsidered therapeutic , and these medications should not interfere with the conduct of 
the study . Subjects with renal impairment should be on a stable regimen of chronic 
medications [ADDRESS_776256] abstain from taking prescription or nonprescription drugs (including vitamins 
and dietary  or herbal supplements), unless specified in Section 6.11.1
,within 7days (or 
14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is longer) 
prior to the first dose of study  medication until completion of the Follow -up Visit, unless ,
in the opi[INVESTIGATOR_571001] ,the medication will not interfere with the 
study . 
Due to the potential for acet ylcholinesterase inhibition with gepotidacin , the followi ng 
medications are prohibited:
Succiny lcholine or other depolarizing muscle relaxants.
Acet ylcholinesterase inhibitors as required for m yasthenia gravis including
edrophonium, py ridostigmine, neostigmine, etc.
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waiv ers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table s are essential and required for stud y conduct.
This section lists the procedures and parameters of each planned study assessme
nt. The 
exact timing of each assessment is listed in the Time and Events Table s,Section 7.1.
The following points must be noted: 
If assessments ar e scheduled for the same nominal time, THEN the assessments 
should occur in the following order:
1. 12- lead ECG
2.vital signs
3.blood draws
Note: The timing of the assessments should allow the blood draw to occur at the exact 
nominal time.
The timing and number o f planned stud y assessments, including safet y and PK 
assessments, may  be altered during the course of the study  based on newl y available  2016N307631_00
2014N2 09329_00 CONFIDENTIA L
BTZ116849
32data (e.g., to obtain data closer to the time of peak plasma concentrations) to ensure 
appropriate monitoring. 
The cha nge in timing or addition of time points for any  planned study assessments 
must be documented in a Note to File which will be approved b y the relevant [COMPANY_004] 
study  team member and then archived in the study sponsor and clinic study  files, but 
this will not co nstitute a protocol amendment. 
The institutional review board (IRB)/ independent ethics committee (IEC) will be 
informed of an y safety issues that require alteration of the safet y monitoring scheme 
or amendment of the informed consent form (ICF) . 
No more than 500 mL of blood will be collected over the duration of the study , 
including an y extra assessments that may  be required. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
337.1. Time and Events Table s
Table 2 Time and Events Table (Groups A , B, C, D, and E)
ProcedureScreening 
(up to 30 days 
prior to Day -1)Check- inTreatment Period
(Days)Follow -up 
(10[±5] days 
post- last dose)
or Early 
TerminationNotes
–1 1 2 3
Confined to clinic X X X XSubjects will be admitted to the clinic on 
Day – 1 and will be discharged on Day 3. 
Confinement will be 4 days and 
3overnight stays
Informed consent X
Inclusion and exclusion criteria X X
Demographics X
Complete physical examination including 
height and weightX
Abbreviated physical examination X X X
Medica l history (includes substance 
usage and history of renal disease)XSubstances: drugs, alcohol, and 
caffeine . Subjects with renal impairment 
should be on a stable regimen of 
chronic medications [ADDRESS_776257] and current medical conditions 
(including renal impairment medical 
history and eGFR )XeGFR as defined in the FDA draft 
guidance for industry, 
“Pharmacokinetics in Patients with 
Impaired Renal Function” [DHHS ,2010] . 
Subjects with normal renal function will 
also be classified based on Clcr.
Serum or urine pregnancy test /FSH X X XSerum (or urine) pregnancy test (if 
WCBP); estradiol and FSH at 
Screening ,as appropriate
HIV antibody, hepatitis B surface antige n,
and hepatitis C antibody testingaX
Drug and alcohol screen X X See Table 6. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
34ProcedureScreening 
(up to 30 days 
prior to Day -1)Check- inTreatment Period
(Days)Follow -up 
(10[±5] days 
post- last dose)
or Early 
TerminationNotes
–1 1 2 3
Laboratory assessments (include liver 
chemistries)X X X XIncluding serum chemistry, hematology
and urinalysis. Results from [ADDRESS_776258] a pharmacogenomics (PGx) 
sample only if the subject has a signed 
consent specific for this purpose. The 
PGx sample can be collected anytime, 
but Day –[ADDRESS_776259] 
different collection intervals. See Table 
3for time points.
Saliva collection for pharmacokineticsc X X X See Table 3for time points.
AE/SAE review X X ==================  X
Concomitant medication review X ==================  X
AE = adverse event, C lcr = estimated creatinine clearance; eGFR = estimated glomular filtration rate, ECG = electrocardiogram, FSH = follicle stim ulating hormone; HIV = human 
immunodeficiency virus; PGx = pharmacogenetic, SAE = serious AE; WCBP =women of childbearing potentia l.
a If test has otherwise been performed within [ADDRESS_776260] dose of study treatment, testing at Screening is not required.
b Informed consent for optional substudies (e.g., genetics research) must be obtained before collecting a sample.
c Subjects in Part 1 only .It should be noted that subjects with renal impairment may be on medications that may prevent saliva collections. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
35Table 3 Safety  and PK A ssessments (Groups A , B, C, D, and E)
Treatment Period
Time point ( hours)
Procedurea Predose 0 0.25 0.5 1 1.5 2 2.5 3 4 6 8 12 24b 36b 48b
12-lead electrocardiogram X X X X X X X X X
Vital signs X X X X X X X X X
Treatment administration 
2-hour IV gepotidacin infusionX
Blood collection for 
pharmacokineticsX X X X X X X X X X X X X X X
Urine collection for 
pharmacokinetics (subjects 
with normal renal function )cX X X X X X X X X X
Urine collection for 
pharmacokinetics (subjects 
with renal impairment)dX X X X X X X
Saliva collectionse X X X X X X X X X X X X X X X
a When coinciding with safety and/or pharmacokinetic assessments, electrocardiograms, vital signs, and pharmacokinetic blood co llections should be performed in said order.
b The 24- , 36-, and 48 -hour postdose time points corres pond to time points on Day 2 and 3, respectively.
c Urine collection intervals for subjects with normal renal function (Group A and Group D) include 0 (pre -dose), 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 12 hours, 
12to 24 hours, 24 to 36hours, and 36 to 48 hours .
d Urine collection intervals for subjects with renal impairment (Group B , Group C, and Group E) include 0 hour (pre -dose), 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 36, and 
36 to 48 hours.
e Subjects in Part 1 only . It should be noted that subjects with renal impairment may be on medications that may prevent saliva collections.  
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
36Table 4 Time and Events Table s (Group F)
ProcedureaScreening 
(up to 
30days prior 
to Day -1)Check
-inTreatment P eriod
(Days)Follow -up 
(10[±5] days 
post- last 
dose) or 
Early 
TerminationNotes
1 2
–1 1 2 3 4 to 6 7 8 9 10
Confined to clinicb X X X X X X X XSubjects will be admitted 
to the clinic on Day –1 
and Day 7, and will be 
discharged on Day 3 
(Period 1) and Day 10
(Period 2) .Confinement 
will be 8 days and 
6overnight stays) total.
Informed consent X
Inclusion and exclusion 
criteriaX X X
Demographics X
Complete physical 
examination including 
height and weightX
Abbreviated physical 
examinationX X X X
Medical history (includes 
substance usage and 
history of renal disease)XSubstances: drugs, 
alcohol, and caffeine.
Subjects with renal 
impairment should be on 
a stable regimen of 
chronic medications 
7days before the first 
dose of study drug on 
Day 1. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
37ProcedureaScreening 
(up to 
30days prior 
to Day -1)Check
-inTreatment P eriod
(Days)Follow -up 
(10[±5] days 
post- last 
dose) or 
Early 
TerminationNotes
1 2
–[ADDRESS_776261] and current medical 
conditions (including renal 
impairment medical 
history and eGFR)XeGFR defined in the 
FDA draft guidance for 
industry, 
“Pharmacokinetics in 
Patients w ith Impaired 
Renal Function” 
[DHHS ,2010].
Serum or urine pregnancy 
test/FSHX X X XSerum (or urine) 
pregnancy test (if 
WCBP); estradiol and 
FSH at Screening as 
appropriate.
HIV antibody, hepatitis B 
surface antigen, and 
hepatitis C antibody 
testingcX
Drug and alcohol screen X X X See Table 6.
Laboratory assessments 
(include liver chemistries)X X X X X XIncluding serum 
chemistry, and 
hemato logy. Results 
from 24 hours after 
dosing should be 
available before 
discharge on Day 3 
(Period 1) and Day 10 
(Period 2)
12-lead ECG X X X X X X X X X X
Vital signs X X X X X X X X X XRespi[INVESTIGATOR_589338]. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
38ProcedureaScreening 
(up to 
30days prior 
to Day -1)Check
-inTreatment P eriod
(Days)Follow -up 
(10[±5] days 
post- last 
dose) or 
Early 
TerminationNotes
1 2
–[ADDRESS_776262] a 
pharmacogenomics 
(PGx) sample only if the 
subject has a signed 
consent specific for this 
purpose. The PGx 
sample can be collected 
anytime, but Day –1 is 
recommended.
Study drug administration Xb Xb
Blood c ollection for 
pharmacokineticsX X X X X XSee Table 5for time 
points.
Urine collection for 
pharmacokineticsX X X X X XSee Table 5for time 
points. Subjects m ay not 
be able to produce a 
urine sample.
Dialysate collections for 
pharmacokineticsX X XSee Table 5for time 
points.
AE/SAE review X X ==================================  X
Concomitant medication 
reviewX================== ================= X
Footnotes continued on the next page. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
39AE = adverse event, eGFR = estimated glomular filtration rate, ECG = electrocardiogram, FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus, 
PGx =pharmacogenetic, SAE = serious AE; WCBP =women of childbearing potential.
a For subjects on hemodialysis (Part 2 [optional] , Group F ), assessments performed on scheduled hemodialysis days are to be done before hemodialysis (except for PK sample 
collect ion, which will be done before and after hemodialysis) .
b Subjects in Group Fwill participate in [ADDRESS_776263] 7 days. Subje cts in Group F will enter the clinic at 
Check- in (Day –1, Period 1 and Day 7, Period 2) before each study drug administration (Day 1 ,Period 1 and Day 8 ,Period 2). On Day 1 (Period 1) and Day 8 ( Period 2), subjects 
in Group F will receive a single dose of study drug as follows: gepotidacin [ADDRESS_776264] 
hemodialysis session of the week (Period 1) and gepotidacin [ADDRESS_776265] hemodialysi s session 
of the week (Period 2). Subjects in Group F will be discharged from the clinic on Day [ADDRESS_776266] dose of study treatment, testing at Screening is not required.
d Informed co nsent for optional substudies (e.g., genetics research) must be obtained before collecting a sample. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
40Table 5 Safety  and Pharmacokinetic A ssessments (Group F)
Treatment Periods 1 and 2
Time point (hours)a
ProcedureaPredose 0 0.25 0.5 1 1.5 2 2.5 3 4 6 8 12 24b 36b 48b
12-lead electrocardiogramX Xc X X X X X X
Vital signsX Xc X X X X X X
Treatment administration 2 -hour 
IV gepotidacin infusiondX
Blood collection for 
pharmacokineticsX X X X X X X X X X X X X X X
Urine collection for 
pharmacokineticseX X X X X X X
Dialysate collection for 
pharmacokineticsfX X X X X
a When coinciding with safety and/or pharmacokinetic assessments, electrocardiograms, vital signs, and pharmacokinetic blood collections should be performed in said order.
b The 24- , 36-, and [ADDRESS_776267] 7 days. Subjects in Group F will enter the clinic at 
Check- in (Day –1, Period 1 and Day 7, Period 2) before each study drug administration (Day 1, Period 1 and Day 8, Period 2). On Day 1 (Perio d 1) and Day 8 (Period 2), subjects 
in Group F will receive a single dose of study drug as follows: gepotidacin [ADDRESS_776268] 
hemodialysis session of the week (Period 1) and gepotidacin [ADDRESS_776269] hemodialysis session 
of the week (Period 2). Subjects in Group F will be discharged from the clinic on Day 10 ,Period 2.
e It should be noted t hat subjects in Group F may not be able to produce urine samples due to their medical condition. All sampling times are relative to the start of the infusion.
f Dialysate fluid will be collected on Day 1 after dosing (Period 1 only) over each 1 -hour collection interval of the hemodialysis session. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
417.2. Screening and Critical Baseline A ssessments
Cardiovascular medical history /risk factors ( as detailed in the eCRF) will be assessed at 
Screening .
The following demographic parameters will be captured: year of birth, sex , race ,and 
ethnicity .
Medical/medication/ family  history  will be assessed as related to the inclusion/exclusion 
criteria listed in Section 5.
7.3. Safet y
Planned time points for all safety assessments are listed in the Time and Events Table s
(Section 7.1). Additional time points for safet y tests such as vital signs, physical exams 
and laboratory  safet y tests may be added during the course of the stud y based on newl y
available data to ensure appropriate safet y monitoring.
7.3.1. Adverse Events and Serious A dverse Events
The definitions of an AE or an SAE can be found in Appendix 5.
The investigator and their designees are responsible fo r detecting, documenting ,and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency for collecting A dverse Event and S erious 
Adverse Event information
Any SAEs assessed as related to study  participation (e.g., protocol
-manda ted 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] product 
will be recorded from the time a subject consents to participate in the stud y up to and 
including an y follow -up contact. 
AEs and SAEs will be collected from the tim e informed consent is obtained until the 
follow -up contact (seeSection [IP_ADDRESS]) at the time points specified in the Time and 
Events Table s (
Section 7.1 ).
Medical occ urrences that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions 
section of the eCRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicate d in 
Appendix 5
.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects . However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the investigator 
must promptly  notify  [COMPANY_004]. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
42NOTE: The method of recording ,evaluating and assessing causality  of AEs and SAEs 
plus procedures f or completing and transmitting SAE reports to [COMPANY_004] are provided in
Appendix 5.
[IP_ADDRESS]. Method of Detecting A dverse Events and S erious Adverse Events
Care will be taken to not introduce bias when detecting AEs and/or SAEs. Open -ended 
and nonleading verbal questioning of the subject is the preferred method to inquire about 
an AE occurrence. Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you t aken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
[IP_ADDRESS]. Follo w-up of A dverse Events and S erious Adverse Events
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts. All SAEs, and nonserious AEs of special interest (as 
defined in Section 4.6.1 )will be followed until resolution, until the condition stabilizes, 
until the event is otherwise explained, or until the subject is lost to follow -up (as defined 
in Section 5.4
).Further information on follow -up procedures is given in Appendix 5.
[IP_ADDRESS]. Regulatory  Reporting Requirements for Serious Adverse Events
Prompt notification by [CONTACT_589357] (even for noninterventional postmarketing studies) is essential so that 
legal obligations and ethical responsibilities towards t he safet y of subjects and the safety 
of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation. [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, IRB/I EC,and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to loc al regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements .
7.3.2. Pregnancy
Details of all pregnancies in female subjects and ,if indicated ,female partners of 
male subjects will be collected after the start of dosing and un til [ADDRESS_776270] 
dose. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
43If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 weeks 
of learning of the pregnancy  and should follow the procedures outlined in Appendix 
7.
7.3.3. Physical Exams
A comple te ph ysical examination will include , at a minimum, assessment of the 
cardiovascular, respi[INVESTIGATOR_696], GI,and neu rological sy stems. Height and weight will 
also be measured and recorded.
A brief ph ysical examination will include, at a minimum ,assessments of the skin,
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses
7.3.4. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_776271] and will 
include sy stolic and diastolic blood pressure ,and pulse rate . Baseline body 
temperature and respi[INVESTIGATOR_268671].
7.3.5. Electrocardiogram
Single [ADDRESS_776272] be conducted in 
accordance with the Laboratory  Manual ,and Protocol Time and Events Tables
(Section 7)
.Laboratory  requisition forms must be completed and samples must be clearl y 
labelled with the subject number, protocol number, clinic number, and visit date. Details 
for the preparation and shipment of samples will be provided b y the laboratory and are 
detailed in the SRM .Reference ranges for all safety  parameters will be provided to the 
clinic by [CONTACT_90633].
If additional nonprotocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF.
Refer to the SRM for appropria te processing and handling of samples to avoid duplicate 
and/or additional blood draws. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
44Hematology , serum chemistry , urinal ysis,and additional parameters to be tested are listed 
in Table 6. 
Table 6 Laboratory  Assessments
Hematology
Platelet Count RBC Indices: WBC count with Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit MCHC Monocytes
Eosinophils
Basophils
Serum Chemistrya
Blood urea nitr ogen Potassium AST Total and direct bilirubin
Creatinine Sodium ALT Total protein
Glucose Calcium Alkaline phosphatase Albumin
Creatine kinase
Routine Urinalysis
Specific gravity
pH, glucose, protein, blood ,and ketones by [CONTACT_589358] e xamination (if blood or protein is abnormal)
Other Screening Tests
eGFR (Section 6.2)
Clcr (Section 6.2)
Hepatitis B surface antigen, hepatitis C antibody, and hu man immunodeficiency virus
Follicle -stimulating hormone and estradiol (as needed in women of nonchildbearing potential only)
Serum test for human chorionic gonadotropin (as needed in women of childbearing potential)
Alcohol (via urine, blood alcohol, or breathalyzer test) and drug screen ( via serum, urine, or saliva) to include, at a 
minimum: amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids, and benzodiazepi[INVESTIGATOR_1651]).
a Details of liver chemistry stoppi[INVESTIGATOR_21357] -upassessments after liver stoppi[INVESTIGATOR_43191] 5.4.1 and Appendix 3.
All laboratory  tests with values that are considered clinically significan tly abnormal 
during participation should be repeated until the values return to normal or baseline. If 
such values do not return to normal within a period judged reasonable b y the investigator, 
theetiology should be identified and the sponsor notified.
7.4. Pharmacokinetics
7.4.1. Blood Sample Collection
The PK blood samples for the analysis of gepotidacin will be collected at the time points 
listed in Section 7.1,Time and Events Tables. The actual date and time of each bl ood 
sample collection will be recorded. The timing of PK samples may  be altered and/or PK 
samples may  be obtained at additional time points to ensure thorough PK monitoring.
For each sample, 3 mL of blood will be drawn via an indwelling catheter and/or dir ect 
venipuncture into tubes containing eth ylenediaminetetraacetate anticoagulant. Details of 
PK blood sample processing, storage, and shippi[INVESTIGATOR_42232]. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
457.4.2. Urine Sample Collection
The PK urine samples for the anal ysis of gepotidacin will be collected at the time points 
listed in Section 7.1, Time and Events Tables. The actual date and time of each urine 
sample collection will be recorded. The timing of PK samples may  be altered and/or PK 
samples may  be obtained at additional time points to ensure thorough PK monitoring.
Details of PK urine sample processing, storage, and shippi[INVESTIGATOR_249208].
7.4.3. Saliva Sample Collection
The PK s aliva samples for parent anal ysisof gepotid acin will be collected from subjects 
in Part 1 at the time points listed in Section 7.1
,Time and Events Tables. The timing of 
saliva samples may  be altered and/or samples may  be obtained at additional time poin ts 
to ensure thorough PK monitoring.
Details of PK saliva sample collection, processing, storage, and shippi[INVESTIGATOR_90866].
7.4.4. Dialy sate Sample Collection
The PK dialy sate samples for anal ysis of gepotidacin will be collected at the time points 
listed in Section 7.1,Time and Events Table s (Table 4and Table 5
; Grou p F only). The 
timing of dialy sate samples may be altered and/or samples may  be obtained at additional 
time points to ensure thorough PK monitoring.
Details of PK dialy sate sample collection, processing, storage ,and shippi[INVESTIGATOR_589339].
7.4.5. Sample A nalysis
Plasma, urine, 
saliva , and dialy sate anal ysis will be performed under the control of 
PTS-DMPK/Scinovo, [COMPANY_004] , the details of which will be included in the SRM. 
Concentrations of gepotidacin will be determined in plasma , urine, saliva, and dialy sate 
samples using the currently  appro ved bioanal ytical methodology .Raw data will be 
archived at the bioanal ytical site (detailed in the SRM).
Since plasma protein binding of gepotidacin is low (33%), onl y total drug concentrations 
will be reported for the 
PK anal ysis.
Once the plasma, urine , saliva , and dial ysate have been analy zed for gepotidacin ,any 
remaining plasma, urine, saliva , and dial ysate may be anal yzed for other 
compound -related metabolites and the results reported under a separate 
PTS-DMPK/Scinovo, [COMPANY_004] protocol. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
467.5. Optional Pharmac okinetic Markers
With the subject’s consent, if a kidney  or bladder tissue sample is collected for a 
nonstudy  purpose, excess tissue may be collected during this study  and may  be used for 
the purposes of measuring drug concentrations of gepotidacin.
7.6. Genetics
Depending on the clinical study  results, optional exploratory pharmacogenomics analy ses 
may be performed to examine the potential relationship between genetic variants and 
clinical endpoints.
The pharmacogenomics samples will be collected according to t he Time and Events 
Tables ( Table 2and Table 4). Information regarding genetic research is included in
Appendix 4.
8. DATA MANAG EMENT
Forthis study , subject data will be entered via an eCRF into Oracle Clinical Remote 
Data Capture S ystem. Subject data will be available for viewing through access to the 
Oracle Clinical Remote Data Capture S ystem. Data provided from other sources will 
be rec eived, reconciled, combined, and transferred to [COMPANY_004] at predetermined time 
points.
Management of clinical data will be performed in accordance with applicable [COMPANY_003] 
standards and data cleaning procedures to ensure the integrity and quality  of the data 
(e.g., removing errors and inconsistencies in the data ). Adverse events and 
concomitant medications terms will be coded using Medical Dictionary  for 
Regulatory  Activities (MedDRA )and a validated medication dictionary , [COMPANY_004]Drug.
The eCRFs (including queries and au dit trails) will be sent at the end of the study  in 
electronic format to [COMPANY_004] to be retained. Each investigator will receive a copy  of their 
site specific data in the same format to maintain as the investigator cop y. In all cases, 
subject initials will not be collected or transmitted.
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
A formal h ypothesis will not be tested; however, an estimation approach will be taken to 
characterize the PK of gepotidacin in subjects with mild, moderate, severe renal 
impairment and in subjects with ESRD (on dialy sis and not on dialy sis) compared with 
matched subjects with normal renal function. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
479.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
The target sample size of [ADDRESS_776273] variations of PK parameters from 1000 mg 2 -hour IV administration 
on Day  1 in the BTZ115198 study  were 26.3%, 27.4%, and 27.6% for the Cmax, from 
AUC from time 0 to infinity  (AUC(0 -∞)), and AUC(0- t), respectivel y [see report of 
Study  BTZ115198].
For a between -subject coefficient of variation of 26.3%, 27.4%, and 27.6%, and a sample 
size of 16 subjects for the subjects with normal renal function and8 subjects for the 
renal lyimpaired group, it is estimated that the half width of the 90% confidence interval
(CI) for the difference on log -scale will be within 21.77%, 22.75%, and 23.00% of the 
point estimate for Cmax, AUC(0 -∞), and AUC(0 -t), respective ly. 
9.2.2. Sample Size Re -estimation or Adjustment
Not applicable.
9.3. Data Analysis Considerations
In general, descriptive summaries will include number of subjects ( n), mean, SD, median, 
minimum, and maximum for continuous variables; and percent for categorical va riables. 
Summaries will present data b y group ,and where appropriate, by  [CONTACT_81510].
9.3.1. Analysis Populations
The Safety P opulation will consist of all subjects who receive at least [ADDRESS_776274] of all subjects in the PK Population, for 
whom valid and evaluable PK parameters were derived. This population will be used in 
the assessment and characterization of PK parameters.
9.3.2. Interim A nalysis
No formal interim anal yses are planned for this study . However, all preliminary  safet y, 
tolerability , and available PK data will be reviewe d internally  at [COMPANY_004] after the 
approximate sample size has been reached in Part 1 and Part 2 (optional). 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
489.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
Pharmacokinetic Analyses
Plasma , urine, and saliva concentrations of gepotidacin will be subjected to PK analy ses 
using noncompartmental methods. Based on the individual concentration time data the 
following parameters will be estimated:
Plasma :
AUC(0 -) Area under the concentration- time curve from time 0 (predose) 
extrapolated to infinite time
AUC(0 -t) Area under the concentration -time curve from time 0 (predose) to time of 
last quantifiable concentration
CL Systemic clearance 
Cmax Maximum observed concentration
λz Terminal -phase rate constant
t1/[ADDRESS_776275] occurrence of Cmax
Vss Volume of distribution at steady -state of parent drug
Vz Volume of distribution of the terminal phase
Urine :
Ae total Total unchanged drug (total amoun t of drug excreted in urine) , calculated 
by [CONTACT_249228](t1 -t2) Amount of drug excreted in urine in a time intervals for predose, 0 to 6, 
6 to 12, 12 to 24, or 24 to 36, and 36 to 48 hou rs after dosing for subjects 
with renal impairment; and predose, 0 to 2 hours, 2 to 4 hours, 4 to 
6 hours, 6 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 
36to 48 hours for subjects with normal renal function
fe% Percentage of the given d ose of drug excreted in urine, calculated as: 
fe%= (Ae total/Dose) × 100
CLr Renal clearance of drug, calculated as: Ae total/AUC(0- t)
Dialy sate (Subjects with ESRD on dialy sis; Group F subjects in Part 2) :
Arem(0 -1) Amount of drug removed by  [CONTACT_589351] 0 to 1 hour after the 
start of hemodial ysis
Arem(1 -2) Amount of drug removed by  [CONTACT_589351] 1 to 2 hours after the 
start of hemodial ysis 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
49Arem(2 -3) Amount of drug removed by  [CONTACT_589351] 2 to 3 hours after the 
start of hemodial ysis
Arem(3 -4) Amount of drug removed by  [CONTACT_589351] 3 to 4 hours after the 
start of hemodial ysis (or to the end of dial ysis if less than 4 hours)
Arem(0 -4) Cumulative amount of drug removed b y hemodialysis from time 0 to 
4hours after the s tart of hemodialy sis (or to the end of dialy sis if less than 
4hours)
AUC(t0- t1) Partial area under the curve estimated from predialy zer samples collected 
from start of dial ysis (t0) to end of dialy sis (t1)
CL D Dialy sis clearance, calculated as the total amount of the anal yte recovered 
in the dialy sate over 4 hours (or the total dial ysis interval if less than 
4hours) divided b y the partial area under the curve during the period of 
dialy sis, which will be calculated using the predialy zer samples
Frem%(0 -4) Fraction (%) of the dose removed b y hemodial ysis from 0 to 4 hours after 
the start of hemodial ysis (or to the end of dial ysis if less than 4 hours)
Plasma concentrations (all subjects) , urine concentrations, and dialy sate concentrations 
(Group F) of gepoti dacin and the associated PK parameters will be listed, and summary  
statistics (n, mean, median, standard deviation [SD], minimum, maximum, and 
coefficient of variation [CV] ) will be presented by [CONTACT_589359]. Mean and 
individual plasma concentration v ersus time profiles will be presented graphically  on 
linear and semilogarithmic scales.
The log- transformed AUC(0 -∞), AUC(0 -t), and Cmax values for gepotidacin in the renal 
impairment groups and normal renal function groups will be compared using an anal ysis 
of variance. Geometric mean ratios between renal impairment groups and normal renal 
function groups, and 90% C Is for the ratios of AUC(0 -∞) and Cmax for gepotidacin will 
be presented.
Linear regression anal ysis will be used to evaluate the relationships between estimated 
renal function and relevant PK parameters (e.g., AUC, Cmax, and CL ). If the data permit 
the id entification of linear functions that fit the data well, the resulting slopes will provide 
a comparison of an y difference in the response of the gepotidacin IV treatment as renal 
function changes.
If the appropriate number of subjects with severe renal impairment and/or subjects with 
ESRD not on dialy sis cannot be enrolled, or their eGFR values cluster at the higher end 
of the range, the PK profiles insubjects with ESRD on hemodialy sis may  be modeled to 
understand the pharmacokinetics for the other groups of subjects with renal impair ment at 
the lower end of the range (<15 mL/min/1.73 m2),as well as for subjects with ESRD not 
on hemodialy sis.
Detailed descriptions of the anal yses in this study  will be presented in the Reporting and 
Analy sis Plan (RAP) . 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
509.4.2. Secondary  Analyses
[IP_ADDRESS]. Safety  Analyses
The following safet y evaluations will be performed:
Monitoring for AEs
Changes in routine clinical laboratory  parameters including hematology , serum 
chemistry , and urinal ysis
Clinically  significant changes in vital sign me asurements or ph ysical examination 
findings 
Changes in 12 -lead ECG measurements
Safety  endpoints will include AEs, clinical laboratory  results (serum chemistry  [including 
liver function parameters], hematology , and urinaly sis), vital sign measurements (bl ood 
pressure andheart rate), [ADDRESS_776276] demographics, medical 
history , and prior and concomitant medications will be summarized by  [CONTACT_227256]. For continuous variables, these summaries will include sample size, 
mean, median, SD, minimum, and maximum.
For categorical variables, the summaries will include frequencies and corresponding 
percentages. No inferential hy pothesis testing will be performed on the safety  variables.
Adverse events will be coded using the MedDRA classification s ystem. 
Treatment -emergent AEs (TEAEs) will be defined as any  AEs, regardless of relationship 
to investigational product, that occur after the dose of investigational product. The 
TEAEs will be summarized by  [CONTACT_589360]. The total number of AEs will be 
summarized by  [CONTACT_229380]. The AEs will be further su mmarized by  [CONTACT_11370] y and 
relationship to the study  drug. If relationship information is missing, the AE will be 
considered treatment related. L istings for the subsets of SAEs and treatment -related SAEs 
will be provided. The number of AEs leading to discontinuation and SAEs will be 
summarized. The incidence of AEs will also be summarized by  [CONTACT_39812].
Clinical laboratory  results, vital sign measurements (systolic and diastolic blood pressure 
and heart rate) , and 12 -lead ECG result s will be summarized by  [CONTACT_589361]. Clinical laboratory  values that are outside of the reference ranges will be 
flagged and evaluated for clinical significance b y the investigator. An y ECG 
abnormalities, including but not limite d to a QTc interval > 500msec or increase in QTc 
from the Screening ECG of ≥60 msec, will be summarized by  [CONTACT_19313]. Phy sical 
examination findings will be listed.
Detailed descriptions of the anal yses in this study  will be presented in the RAP. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
519.4.3. Other Analyses
[IP_ADDRESS]. Exploratory  Analyses
Saliva ( subjects in Part 1 only):
AUC(0 -) Area under the concentration- time curve from time 0 (predose) 
extrapolated to infinite time
AUC(0 -t) Area under the concentration- time curve from time 0 (predose) to time of 
last quantifiabl e concentration
CL Systemic clearance 
Cmax Maximum observed concentration
λz Terminal -phase rate constant
t1/[ADDRESS_776277] occurrence of Cmax
Vz Volume of distribution of the terminal phase
Saliva concentrations (subjects in Part 1 only; as data permit ) of gepotidacin and the 
associated PK param eters will be listed, and summary  statistics (n, mean, median, SD, 
minimum, maximum, and CV ) will be presented by  [CONTACT_589349]. Mean and 
individual saliva 
concentration versus time profiles will be presented graphically  on 
linear and semilogarithmic scales.
An exploratory  anal ysis will be performed to explore the relationship between saliva and 
plasma concentrations. Natural log-transformed saliva gepotidacin concentrations versus 
the natural log -transformed plasma gepotidacin concentrations will be pl
otted and a 
regression line will be fitted. A similar anal ysis will also be performed for the AUC(0 -), 
AUC(0 -t), and Cmax.
Detailed descriptions of the anal yses in this study  will be presented in the RAP.
10. STUDY GOVERNANCE CONSIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Cons ent Process
Prior to initiation of a clinic, [COMPANY_004] will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with International 
Conference on Harmonisation (I CH) Good Clinical Practice (GCP) and applicab le 
country -specific regulatory  requirements. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
52The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with ICHGCP, all applicable subject 
privacy  requirement s, and the guiding principles of the current version of the Declaration 
of Helsinki. This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable .
Obtaining signed inf ormed consent.
Investigator reporting requirements (e.g.,reporting of AEs/SAEs/protocol deviations 
to the IRB/IEC).
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, or 
both.
Signed informed consent must be obtained for e ach subject prior to participation in 
the study .
The IRB/IEC, and where applicable the regulatory authority , approve the clinical 
protocol and all optional assessments, including genetic research .
Optional assessments (including those in a separate protoco l and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.
Approval of the optional assessments may  occur after approval is granted for the 
clinical prot ocol where required b y regulatory  authorities. I n this situation, written 
approval of the clinical protocol should state that approval of optional assessments is 
being deferred and the study , with the exception of the optiona l assessments, can be 
initiated .
10.3. Qualit y Control (Study  Monitoring)
In accorda nce with applicable regulations including GCP and [COMPANY_004] /[COMPANY_003] procedures, 
[COMPANY_004] /[COMPANY_003] monitors will contact [CONTACT_589362]: the protocol, study requirements, and their 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] /[COMPANY_003] requirements.
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF will 
serve as the source document.
[COMPANY_004] /[COMPANY_003] will monitor the study and clinic activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approv ed protocol and any other 
study  agreements, GCP, and all applicable regulatory  requirements. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
53The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents .
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the clinic records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after complet ion of the study . 
In the event of an assessment, audit ,or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) ,and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss the 
conduct of the stud y, an y findings/relevant issues ,and to implement any  corrective 
and/or preventative actions to address any findings/issues identified.
10.5. Stud y and Clinic Closure
Upon completion or premature discontinuation of th e study , the [COMPANY_004] /[COMPANY_003] monitor 
will conduct clinic closure activities with the investigator or clinic staff, as 
appropriate, in accorda nce with applicable regulations including GCP, and [COMPANY_004] /[COMPANY_003]
standard operating procedures.
[COMPANY_004] /[COMPANY_003] reserves the right to temporarily  suspend or prematurely  discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues or 
severe noncompliance . For multi -center studies, this can occur a t one or more or at 
all clinics.
If [COMPANY_004]/[COMPANY_003] determines such action is needed, [COMPANY_004]/[COMPANY_003] will discuss the reasons for 
taking such action with the investigator or the head of the medical institution (where 
applicable). When feasible, [COMPANY_004]/[COMPANY_003] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004]/[COMPANY_003]
willpromptly  inform all investigators ,head sof the medical institution s(where 
applicable) and /or instituti on(s) conducting the study . [COMPANY_004]/[COMPANY_003] will also promptly  
inform the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.
If required b y applicable regulations, the investigator or the h ead of the medical 
institution (whe re applicable) must inform the IRB/IECpromptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study, the investigator or the head of the medical institu tion 
(where applicable) must maintain all clinic study  records (except for those required 
by [CONTACT_1206] ), in a safe and secure location.
The records must be maintained to allow eas y and timely retrieval when needed 
(e.g., for a [COMPANY_004] audit or regulatory inspection) and must be available for review in  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
54conjunction with an assessment of the facilit y, supporting s ystems, and relevant 
clinic staff.
Where permitted b y local laws/regulations or institutional policy, some or all of t hese 
records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and re trieval standards, including 
regenerating a hard cop y, if required. Furthermore, the investigator must ensure there 
is an acceptable back -up of these reproductions and that an acceptable quality  control 
process exists for making these reproductions.
[COMPANY_004]/[COMPANY_003] will inform the investigator of the time period for retaining these records 
to comply  with all applicable regulatory  requirements. The minimum retention time 
will meet the strictest standard appl icable to that clinic for the study , as dictated by  
[CONTACT_65406], [COMPANY_004]/[COMPANY_003]
standards/procedures, and/or institutional requirements.
The investigator must notify  
[COMPANY_004]/[COMPANY_003] of an y changes in the archival arrangemen ts, 
including, but not limited to, archival at an off -site facility  ortransfer of ownership 
of the records in the event the investigator is no longer associated with the clinic .
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Public ally Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report. The investigator will be provided 
reasonable access t o statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other 
mutually -agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results. The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
5511. REFERENCES
Bax BD, Chan PF, Eggleston DS, Fosberry  A, Gentry  DR, Gorrec F, et al. Ty pe IIA 
topoisomerase inhibition by  a new class of antibacterial agents. Nature . 
2010;466(7309):935-40.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in age- related macular 
degeneration (AMD) susceptibility  gene CFH and treatment response of AMD: a 
meta -analysis. PloS ONE. 2012; 7: e42464.
Department of Health and Huma n Services (DHHS), Food and Drug Administration, 
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research 
(US). Guidance for Industry:  Drug- Induced Liver Injury:  Premarketing Clinical 
Evaluation. July  2009. [28 screens]. Avai lable from:  
http://www.fda.gov/ucm/groups/fdagov -public/@fdagov -drugs -
gen/documents/document/ucm174090.pdf
Department of Health and Human Services (DHHS), Food and Drug Administration, 
Center for Drug Evaluation and Research, Center for Biologics Evaluati on and Research 
(US). Draft Guidance for I ndustry :  Pharmacokinetics in Patients with I mpaired Renal 
Function –Study  Design, Data Anal ysis, and Impact on Dosing and Labeling. March 
2010. [21 screens]. Available from:  http://www.fda.gov/ucm/groups/fdagov -
public/@fdagov -drugs -gen/documents/document/ucm204959.pdf
GlaxoSmithKline Document Number 2012N131922_00. Anin vitro study of b1ood cell 
association of [COMPANY_004]2140944 in mouse, rat, dog, monkey , and human. 2012.
GlaxoSmithKline Document Number 2012N156820_00. Elimination and tissue 
distribution of radioactivity  in the male intact and male bile duct -cannulated long evans 
rat following a single intravenous (100 mg free base/kg) or oral (150 mg free base/kg) 
administration of [14C]-[COMPANY_004]2140944 mesy late dehy drate. 2013.
GlaxoSmithKline Document Number 2013N170240_00. In vitro protein binding of 
[14C]-[COMPANY_004]2140944 in human plasma . 1995.
GlaxoSmithKline Document Number 2014N189951_00 Study  ID BTZ115774. An 
open -label, non -randomized, two -period, cross -over, mass balance study  to investigate 
the recovery , excretion and pharmacokinetics of 14C-[COMPANY_004]2140944 administered as a 
single intravenous and single oral dose to healthy  adult male subjects. 2014.
GlaxoSmithKline Document Number 2014N198291_00 Study  ID BTZ115198. A two 
partstudy  to evaluate safety , tolerability , and pharmacokinetics of single and repeat IV 
doses of [COMPANY_004]2140944 in healthy  adult subjects. 2014.
GlaxoSmithKline Document Number 2015N227098_00 Study  ID BTZ115775: 
Population pharmacokinetic -pharmacod ynamic analy sis of a Phase I, randomized, 
double -blinded, placebo -and moxifloxacin -controlled, [ADDRESS_776278] of [COMPANY_004]2140944 on cardiac conduction as assessed b y 12-lead 
electrocardiogram in healthy  volunteers. 2015. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
56GlaxoSmithKline Document Number 2015N243789_00 Study  ID BTZ116704. A 
Phase II, randomized, two -part, multicenter, dose -ranging stud y in adult subjects 
evaluating the safet y, tolerability, and efficacy of [COMPANY_004]2140944 in the treatment of 
subjects with suspected or confirmed gr am-positive acute bacterial skin and skin structure 
infections. 2015.
GlaxoSmithKline Document Number CM2010/[ZIP_CODE]/02. [COMPANY_004]2140944 Investigator’s 
Brochure. 2014.
Gorin MB. Genetic insights into age -related macular degeneration: Controversies 
addressing risk , causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467-486.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th ed. [LOCATION_001]: Ardent Media, 2007(a): 24. Table 3-2.
Hatcher RA, Trussell J, Nelson A L, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th ed. [LOCATION_001]: Ardent Media, 2007(b): 28.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, 
editors. Contraceptive Technology . 20thed. Atlanta, Georgia : Ardent Media, Inc., 2011: 
50.Table 3-2.
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et. al. 
Pharmacokinetics of acetaminophen -adducts in adults with acetaminophen overdose and 
acute liver failure. Drug Metab Dispos 2009; 37(8):1779-84. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
5712. APPENDICES
12.1. Appendix 1:Abbreviations and Trademarks
Abbrev iations
AE adverse event
Ae total total unchanged drug
Ae (t1 -t2) amount of drug excreted in urine in a time interval
ALT alanine aminotransferase 
Arem amount of drug removed by  [CONTACT_589363](0 -1) amount of drug removed by  [CONTACT_589351] 0 to 
1hour after the start of hemodialy sis
Arem(1 -2) amount of drug removed by  [CONTACT_589351] 1 to 
2hours after the start of hemodialy sis
Arem(2 -3) amount of drug removed by  [CONTACT_589351] 2 to 
3hours after the start of hemodialy sis
Arem(3 -4) amount of drug removed by  [CONTACT_589351] 3 to 
4hours after the start of hemodialy sis (or to the end of 
dialy sis if less than 4 hours)
Arem(0 -4) cumulative amount of drug removed b y hemodialysis from 
time 0 to 4 hours after the start of hemodial ysis (or to the 
end of dial ysis if less than 4 hours)
AUC area under the plasma concentration -time curve
AUC (0-) area under the concentration -time curve from time 0 to 
infinity
AUC (0-t) area under the concentration -time curve from time [ADDRESS_776279] quantifiable concentration (t)
AUC (t0-t1) Partial area under the curve estimated from predialy zer 
samples collected from start of dial ysis (t0) to end of 
dialy sis (t1)
bpm beats per minute
CI confidence interval
CL systemic clearance
Clcr creatinine clearance
CL D dialy sis clearance
CLr renal clearance
Cmax maximum observed concentration
DNA deox yribonucleic acid
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomular filtration rate
ESRD end-stage renal disease
FDA [LOCATION_002] Food and Drug Administration
fe% percentage of the given dose of drug excreted in urine 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
58Frem%(0 -4) fraction (%) of the dose removed by  [CONTACT_589352] 0 to 
4hours after the start of hemodialy sis (or to the end of 
dialy sis if less than 4 hours)
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
[COMPANY_004] GlaxoSmithKline
HIV human immunodeficiency virus
HRT hormone replacement thera py
IB Investigator’s Brochure
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IRB Institutional Review Board
IV intravenous
MedDRA Medical Dictionary  for Regulatory  Activities
mm Hg millimeters of mercury
msec millise cond
PBPK physiologicall y-based pharmacokinetic
PK pharmacokinetic
QTc corrected QT interval ; the measure of time between the start 
of the Q wave and the end of the T wave
QTcF corrected QT interval using the Fridericia formula
RAP Reporting and Anal ysis Plan
SAE serious adverse event
SRM Study  Reference Manual
t1/[ADDRESS_776280] upper limit of normal
Vss volume of distribution at steady -state of parent drug
Vz volume of distribution of the te rminal phase
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_589364] 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
5912.2. Appendix 2:Liver Chemistry  Stoppi[INVESTIGATOR_589340] I Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_589341]  
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must  refer to Liver Safety Required Actions and Fol low up Asses sments  section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5 , if measur ed*
Liver safety  required actions and follow -up assessments section can be found in 
Appendix 3.  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
6012.3. Appendix 3: Liver Safety  Required A ctions and Follow -up 
Assessments
Phase I liver chemistry  stoppi[INVESTIGATOR_339215] y and 
to evaluate liver event etiology  (in alignment with the FDA guidance, “Drug -Induced 
Liver Injury : Premarketing Clinical Evaluation,” [ DHHS , 2009].
Phase I Liver Chemistry Stoppi[INVESTIGATOR_90966] -up Assessments
Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_53053]- absoluteALT ≥3× ULN
If ALT ≥3× ULN AND bilirubina,b2× ULN (>35% direct bilirubin) or INR>1.5, 
report as an SAE.
See additional actions and follow -up assessments listed below .
Required Actions and Follow -up Assessments Following Liver Stoppi[INVESTIGATOR_159833]-Up Assessments
Report the event to [COMPANY_004] within 24 hours
Complete the Liver Event CRF, and 
complete an SAE data collection tool if the 
event also meets the criteria for an SAEb
Perform liver event follow -upassessments 
Monitor the subject until liver c hemistries 
resolve, stabilize , or return to within baseline 
(see MONITORING below)
MONITORING:
If ALT ≥3× ULN AND bilirubin 2× ULN or 
INR>1.5
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow -upassessments within 
24hours
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize, or return to 
within baseline
A specialist or hepatology consultation is 
recommended
If ALT ≥3× ULN AND bilirubin <2 × ULN and 
INR ≤1.5:Viral hepatitis serologyc
Serum creatine phosphokinase and lactate 
dehydrogenase.
Fractionate bilirubin, if total bilirubin
2 ×ULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications r eport form 
including acetaminophen, herbal remedies, 
other over the counter medications.
Record alcohol use on the liver event 
alcohol intake case report form
If ALT ≥3× ULN AND bilirubin 2× ULN or 
INR>1.5:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
61Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_53056]
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow -up assessm ents within 
24to 72 hours
Monitor subjects weekly until liver 
chemistries resolve, stabilize, or return to 
within baselineglobulins).
Serum acetaminophen adduct 
high-performance liquid chromatography
assay (quantifies potential acetaminophen 
contribution to liver inju ry in subjects with 
definite or likely acetaminophen use in the 
preceding week [James , 2009 ]. NOTE: not 
required in China .
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and/or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy eCRF forms.
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; eCRF = electronic case 
report form; [COMPANY_004] = GlaxoSmithKline; IgM = Immunoglobulin M; INR = international normalized ratio; 
SAE =serious adverse event; ULN =upper limit of normal.
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatm ent for that subject if ALT 3× ULN and bilirubin 2× ULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver inj ury. 
b All events of ALT 3× ULN and bilirubin 2× ULN (>35% direct bilirubin) or ALT 3× ULN and INR >1.5, if INR 
measured, which may indicate severe liver injury (possible “Hy’s Law”), must be reported as an SAE (excluding 
studies of hepatic impairme nt or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants.
c Includes: hepatitis A IgM antibody; hepatitis B surface antigen and hepatitis B Core Antibody (IgM); hepatitis C 
RNA; cy tomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing); hepatitis E IgM antibody. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
6212.4. Appendix 4:Genetic Research
Genetic Research Objectives and A nalyses
Naturall y occ urring genetic variation may  contribute to interindividual variability  in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response t o therapy , and could help to explain some clinical study  outcomes. For 
example, genetic variants associated with age-related macular degeneration are reported 
to account for much of the risk for the condition [Gorin , 2012] with certain variants 
reported to influence treatment response [Chen, 2012] . Thus, knowledge of the genetic 
etiology  of disease may  better inform understanding of disease and the development of 
medicines. Additiona lly, genetic variability  may  impact the pharmacokinetics 
(absorption, distribution, metabolism, and elimination), or pharmacody namics 
(relationship between concentration and pharmacologic effects or the time course of 
pharmacologic effects) of a specific m edicine ,and/or clinical outcomes (efficacy  and/or 
safet y) observed in a clinical study.
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including gepotidacin or any  concomitan t medicines
Genetic data may  be generated while the study  is underway  or following completion of 
the study . Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (wh ole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above. Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objecti ves.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a RAP prior to initiation of the 
analysis. Planned anal yses and results of genetic investigations will be re ported either as 
part of the clinical RAP and study  report, or in a separate genetics RAP and report, as 
appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research. Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
63A [ADDRESS_776281] has provided informed consent for genetic 
research. Instructions for collection and shippi[INVESTIGATOR_589342]. The DNA from the blood sample may  undergo quality  
control anal yses to confirm the integrit y of t he sample. If there are concerns 
regarding the quality of the sample, then the sample may  be destroy ed. The blood 
sample is taken on a single occasion unless a duplicate sample is required due to an 
inability  to utilize the original sample.
The genetic sam ple is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study . This number can be traced or linked back to the 
subject by  [CONTACT_589365]. Coded samples do not carry  personal identifiers
(such as a name [CONTACT_24004] y number). 
Samples will be stored securel y and may be kept for up to [ADDRESS_776282] 
completes the study  or [COMPANY_004] may  destro y the samples sooner. [COMPANY_004] or those working with 
[COMPANY_004] (for example, other researchers)
,will only use samples collected from the study  for 
the purpose stated in this protocol and in the ICF. Samples may  be used as part of the 
development of a companion diagnostic to support the [COMPANY_004] medicinal product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study . Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subjec t who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collect ed:
Continue to participate in the genetic research ,in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests samp le destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the 
clinic study  records . 
Genoty pe data may  be generated duri ng the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future resea rch. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
64Genetic data that has been anal yzed at the time of withdrawn consent will continue 
to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destroy ed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process. In this instance a sample destruction form will not be available to 
include in the clinic files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately ,andmay publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined. Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
6512.5. Appendix 5: Definition of and Procedures for Recording , 
Evaluati ng, Follow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y asso ciated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can ,therefore ,be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , serum chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs m easurements), 
including those that worsen from baseline, and felt to be clinically  significant in the 
medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in fre quency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible 
suicidal/self- harming inten t. This should be reported regardless of sequelae).
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
66convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event is defined as any untoward medical occurrence that, at any 
dose:
a.Results in death
b.Is life -threatening
NOTE:
The term “life-threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event. I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatm ent that would not have been appropriate in the phy sician’s 
office or out -patient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_9236], the 
event is serious. Whe n in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/ incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, naus ea, vomiting, diarrh oea, influenza, 
and accidental trauma (e.g. ,sprained ankle) which may interfere or prevent every day 
life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations: 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
67Medical or scie ntific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951]. These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room ,or at home for allergic bronchospasm, blood dy scrasias ,or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse .
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3 ×ULN and total bilir ubin*2 ×ULN (>35% direct), or
ALT 3 ×ULN and INR**>1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick. I f fractionation is unavailable and ALT 3 ×ULN 
and total bi lirubin  2 × ULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants. If an INR measurement is obtained, the value is to be 
recorded on the SAE Form.
12.5.3. Definition of Cardiovascular Events
Cardiovascular Events Definition:
Investigators will be required to fill out the specific Cardiovascular event page of the 
eCRF for the following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
6812.5.4. Recording of A dverse Events and S erious Adverse E vents
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the e CRF .
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE eCRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
12.5.5. Evaluating Adverse E vents and S erious Adverse Ev ents
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y according to the US National Institute of Allergy and Infectious 
Diseases DMID criteria for toxicity  assessment ( Appendix 6).
An event is defined as “serious” when it meets at least one of the predefined outcomes as 
described in the definition of an SAE (Section 12.5.2 ).
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A “reasonable possibility ”is meant to convey  that there are facts, evidence, or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the ev ent to the study  
treatment will be considered and investigated.
The investigator will also consult the IB and/or Product Information, for marketed 
products, in the determination of his/her assessment. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
69For each AE/SAE the investigator must document in the m edical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004]. However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A dverse Events and S erious Adverse Events
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist. This may  include additional laboratory tests or 
investigations, histopathological examinations or consultation with other health care 
professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  postm ortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.5.6. Reporting of S erious Adverse E vents to G SK
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool.
If the electronic s ystem is unavailable for greater than 24 hours, the clinic will use 
the paper SA E data collection tool and fax it to the medical monitor or the SAE 
coordinator .
The clinic will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given clinic , the electronic data collection t ool (e.g., 
InForm system) will be taken off- line to prevent the entry  of new data or changes to 
existing data .
If a clinic receives a report of a new SAE from a study  subject or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
70taken off -line, the clinic can report this information on a paper SAE form or to the 
medical m onitor or the SAE coordinator b y telephone.
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
7112.6. Appendix 6:Division of Microbiology  and Infectious Disease 
Adult Toxicity  Tables for A dverse Event A ssessment
ESTIMATING SEVERITY GRADE: For abnormalities NOT found elsewhere in the 
Toxicity  Tables, use the scale below to estimate grade of severit y:
GRADE 1 MildTransient or mild discomfort (<48 hours); no medical 
intervention/therapy required
GRADE 2 ModerateMild to moderate limitation in activity –some assistance may 
be needed; no or minimal medical intervention/th erapy 
required
GRADE 3 SevereMarked limitation in activity, some assistance usually 
required; medical intervention/therapy required, 
hospi[INVESTIGATOR_249212] 4 Life-threateningExtreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, 
hospi[INVESTIGATOR_249213] -THREATENING AEs: ANY clinical event deemed by  [CONTACT_126745]- threatening should be considered a Grade 4 event. 
Clinical events considered to be serious or life -threatening include, but are not limited to: 
seizures, coma, tetan y, diabetic ketoacidosis, disseminated intravascular coagulation, 
diffuse petechiae, paral ysis, acute ps ychosis, and severe depression.
COMMENTS REGARDING T HE USE OF THESE TABLES
Standardized and commonly  used toxicity  tables ( Division of AI DS [DAI Ds], 
National Cancer Institute’s Common Toxicity  Criteria, and World Health 
Organization) have been adapted for use b y the DAIDs and modified to better meet 
the nee ds of participants in Division of Microbiology  and Infectious Diseases trials.
For parameters not included in the following Toxicity  Tables, sites should refer to the 
“Guide for Estimating Severity Grade” located above.
Criteria are generall y grouped by  [CONTACT_44749].
Some protocols may  have additional protocol specific grading criteria, which will 
supersede the use of these tables for specified criteria. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
72HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin 9.5 to 10.5 mg/dL 8.0 to 9.4 gm/dL 6.5 to 7.9 gm/dL <6.5 gm/dL
Absolute neutrophil count 1000 to 1500 /mm3 750 to 999 /mm3 500 to 749 /mm3 <500 /mm3
Platelets 75,000 to 99,999 /mm3 50,000 to 74,999 /mm3 20,000 to 49,999 /mm3 <20,000 /mm3
White Blood Cells 11,000 to 13,000 /mm3 13,000 to 15,000 /mm3 15,000 to 30,000 /mm3 >30,000 or <1000 /mm3
% Polymorphonuclear leukocytes + b and 
cells>80% 90 to 95% >95% N/A
Abnormal FibrinogenLow: 100 to 200 mg/dL
High: 400 to 600 mg/dLLow: <100 mg/dL
High: >600 mg/dLLow: <50 mg/dL
High: N/AFibrinogen associ ated with gross bleeding or 
with disseminated coagulation
Fibrin Split Product 20 to 40 mcg/mL 41 to 50 mcg/mL 51 to 60 mcg/dL >60mcg/dL
Prothrombin Time 1.01 to 1.25 ULN 1.26 to 1.5 ULN 1.51 to 3.0 ULN >3ULN
Activated Partial Thromboplastin 1.01 to 1.66 ULN 1.67 to 2.33 ULN 2.34 to 3 ULN >3ULN
Methemoglobin 5.0 to 9.9% 10.0 to 14.9% 15.0 to 19.9% >20%
N/A = not applicable; ULN = upper limit of normal.  
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
73CHEMISTRIES
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to 135 mEq/L 123 to 129 mEq/L 116 to 122 mEq/L<116 mEq/L or abnormal sodium withmental 
status changes or seizures
Hypernatremia 146 to 150 mEq/L 151 to 157 mEq/L 158 to 165 mEq/L>165 mEq/L or abnormal sodium withmental 
status changes or seizures
Hypokalemia 3.0 to 3.4mEq/L 2.5 to 2.9 mEq/L2.0 to 2.4 mEq/L or intensive 
replacement therapy of 
hospi[INVESTIGATOR_91536]<2.0 mEq/L or abnormal potassium with
paresis, ileus, or life -threatening arrhythmia
Hyperkalemia 5.6 to 6.0 mEq/L 6.1 to 6.5 mEq/L 6.6 to 7.0 mEq/L>7.0 mEq/L or abnormal potassium with
life-threatening arrhythmia
Hypoglycemia 55 to 64 mg/dL 40 to 54 mg/dL 30 to 39 mg/dL<30mg/dL or abnormal glucose withmental 
status changes or coma
Hyperglycemia
(nonfasting and no prior 
diabetes)116 to 160 mg/dL 161 to 250 mg/dL 251 to 500 mg/dL>500 mg/dL or abnormal glucose with
ketoacidosis or seizures
Hypocalcemia
(corrected for albumin)8.4 to 7.8 mg/dL 7.7 to 7.0 mg/dL 6.9 to 6.1 mg/dL<6.1 mg/dL or abnormal calcium with
life-threatening arrhythmia or teta ny
Hypercalcemia
(corrected for albumin)10.6 to 11.5 mg/dL 11.6 to 12.5 mg/dL 12.6 to 13.5 mg/dL>13.5 mg/dL or abnormal calcium with
life-threatening arrhythmia
Hypomagnesemia 1.4 to 1.2 mEq/L 1.1 to 0.9 mEq/L 0.8 to 0.6 mEq/L<0.6 mEq/L or abnormal ma gnesium with
life-threatening arrhythmia
Hypophosphatemia 2.0 to 2.4 mg/dL1.5 to 1.9 mg/dL or 
replacement Rx required1.0 to 1.4 mg/dL
intensive therapy or hospi[INVESTIGATOR_126693]<1.0 mg/dL or abnormal phosphate with
life-threatening arrhythmia
Hyperb ilirubinemia (when 
accompanied by [CONTACT_126746])1.1 to <1.25 ULN 1.25 to <1.5 ULN 1.5 to 1.75 ULN >1.75 ULN
Hyperbilirubinemia (when other 
liver function tests are in the 
normal range)1.1 to <1.5 ULN 1.5 to <2.0 ULN 2.0 to 3.0 ULN >3.0ULN
Blood urea nitrogen 1.25 to 2.5 ULN 2.6 to 5 ULN 5.1 to 10 ULN >10ULN
Hyperuricemia (uric acid) 7.5 to 10.0 mg/dL 10.1 to 12.0 mg/dL 12.1 to 15.0 mg/dL >15.0 mg/dL
Creatinine 1.1 to 1.5 ULN 1.6 to 3.0 ULN 3.1to 6.0 ULN >6ULN or dialysis required
Rx = therapy; ULN = upper limit of normal. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
74ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
Aspartate aminotransferase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Alanine aminotransferase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Gamma to glutamyl transferase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Alkaline Phosphatase 1.1 to <2.0 ULN 2.0 to <3.0 ULN 3.0 to 8.0 ULN >8.0ULN
Amylase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
Lipase 1.1 to 1.5 ULN 1.6 to 2.0 ULN 2.1 to 5.0 ULN >5.1ULN
ULN = upper limit of normal.
URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Proteinuria1+ or
200mg to 1 gm loss/day2 to 3+ or
1 to 2 gm loss/day4+ or
2 to 3.5 gm loss/dayNephrotic syndrome or
>3.5 gm loss/day
HematuriaMicroscopic only
<10RBC/ HPFGross, no clots
>10RBC/ HPFGross, with or without clots,
or red blood cells castsObstructive or 
required transfusion
HPF = high-powered field; RBC = red blood cells. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
75CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac rhythmN/A Asymptomatic, transient signs, no 
Rx requiredRecurrent/persistent; symptomatic 
Rx requiredUnstable dysrhythmia; 
hospi[INVESTIGATOR_589343] t 
required
HypertensionTransient increase >20 mmHg;
no treatment Recurrent, chronic increase 
>20mmHg;
treatment required Acute treatment required; 
outpatient treatment or 
hospi[INVESTIGATOR_589344] 
<20beat/min or decreased by 
<10mmHg systolic BP.
No treatment requiredSymptoms due to orthostatic 
hypotension or BP decreased by 
<20mmHg systolic; correctable with 
oral fluid treatme ntRequires IV fluids;
no hospi[INVESTIGATOR_249216] <60 mmHg 
or end organ damage or shock;
requires hospi[INVESTIGATOR_268681]/moderate asymptomatic 
effusion, no treatmentSymptomatic effusion; pain; EKG 
changesTamponade; pericardiocentesis or 
surgery required
Hemorrhage, Blood Loss Microscopic/occult Mild, no transfusion Gross blood loss; 
1 to 2 units transfusedMassive blood loss; >3 units 
transfused
BP = blood pressure; EKG = el ectrocardiogram; IV = intravenous; N/A = not applicable; Rx = therapy
RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
CoughTransient; no treatment Persistent cough; treatment 
responsiveParoxysmal cough; uncontrolled 
with treatmentN/A
Bronchospasm, AcuteTransient; no treatment; FEV 170 
to 80% of peak flowRequires treatment; normalizes 
with bronchodilator; FEV 150 to 
70% of peak flowNo normalization with 
bronchodilator; FEV 125 to 50 % of 
peak flow; or retractions presentCyanosis: FEV 1<25%  of peak
flow; or intubation necessary
DyspneaDyspnea on exertion Dyspnea with normal activity Dyspnea at rest Dyspnea requiring oxygen 
therapy
N/A = not applicable; FEV 1= forced expi[INVESTIGATOR_3741] 1 second 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
76GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
NauseaMild or transient; maintains 
reasonable intakeModerate discomfort; intake 
decreased significantly; some 
activity limitedNo significant intake; requires IV 
fluidsHospi[INVESTIGATOR_249217]1 epi[INVESTIGATOR_85712] 24 hours 2 to 5 epi[INVESTIGATOR_11630] 24 hours >6 epi[INVESTIGATOR_11630] 24 hours or 
needing IV fluidsPhysiologic consequences 
requiring hospi[INVESTIGATOR_589345]; 3 to 4 loose 
stools/day or mild diarrh oea 
lasting <1 weekModerate or persistent; 5 to 
7loose stools/day or diarrh oea 
lasting >1 week>7 loose stools/day or bloody 
diarrho ea; or orthost atic 
hypotension or electrolyte 
imbalance or >2L IV fluids 
requiredHypotensive shock or physiologic 
consequences requiring 
hospi[INVESTIGATOR_268683]/
DysphagiaMild discomfort; no difficulty 
swallowingSome limits on eating/drinking Eating/talking very limited; unable 
to swallow solid foodsUnable to drink fluids; requires IV 
fluids
IV = intravenous. 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
77NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Neuro- CerebellarSlight incoordination 
dysdiadochokinesisIntention tremor, dysmetria, slurred 
spee ch; nystagmusLocomotor ataxia Incapacitated
PsychiatricMild anxiety or depression Moderate anxiety or depression; 
therapy required; change in normal 
routineSevere mood changes requiring therapy; 
or suicidal ideation; or aggressive 
ideationAcute psycho sis requiring 
hospi[INVESTIGATOR_059]; or suicidal 
gesture/attempt or hallucinations
Muscle strengthSubjective weakness; no objective 
symptoms/signsMild objective signs/symptoms; no 
decrease in functionObjective weakness; function limited Paralysis
Paresthesi a
(burning, tingling, etc.)Mild discomfort; no treatment 
requiredModerate discomfort; non -narcotic 
analgesia requiredSevere discomfort; or narcotic analgesia 
required with symptomatic improvementIncapacitating; or not responsive 
to narcotic analgesia
NeurosensoryMild impairment in sensation 
(decreased sensation, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold in great 
toes) in focal area or symmetrical 
distribution; or change in taste, 
smell, vision, and/or hearingModerate impairment (moderately 
decreased sensa tion, e.g., 
vibratory, pi[INVESTIGATOR_29107], hot/cold to 
ankles) and/or joint position or mild 
impairment that is not symmetricalSevere impairment (decreased or loss of 
sensation to knees or wrists) or loss of 
sensation of at least moderate degree in 
multiple differe nt body areas (i.e., upper 
and lower extremities)Sensory loss involves limbs and 
trunk; paralysis; or seizures 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
78MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia 
(joint pain)Mild pain not interfering with function Moderate pain, analgesics a nd/or pain 
interfering with function but not with ADLSevere paid; pain and/or analgesics 
interfering with ADLDisabling pain
ArthritisMild pain with inflammation, erythema or 
joint swelling, but  not interfering with 
functionModerate pain with inflamma tion, erythema or 
joint swelling; interfering with function but not 
with ADLSevere pain with inflammation, erythema 
or joint swelling, and interfering with ADLPermanent and/or 
disabling joint 
destruction
MyalgiaMyalgia with no limitation of activity Muscle tenderness (at other than injection site) 
or with moderate impairment of activitySevere muscle tenderness with marked 
impairment of activityFrank myonecrosis
ADL = activities of daily living.
SKIN
Grade 1 Grade 2 Grade 3 Grade 4
MucocutaneousErythema; pruritus Diffuse, maculo papular rash, dry 
desquamationVesiculation or moist 
desquamation or ulcerationExfoliative dermatitis, mucous membrane 
involvement or erythema, multiforme or suspected 
Stevens- Johnson or necrosis requiring surgery
Induration <15mm 15 to 30 mm >30mm N/A
Erythema <15mm 15 to 30 mm >30mm N/A
Edema <15mm 15 to 30 mm >30mm N/A
Rash at injection site <15mm 15 to 30 mm >30mm N/A
Pruritus Slight itching at injection site Moderate itching at injection extremity Itching over entire body N/A
N/A = not applicable.
SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Allergic reaction Pruritus without rash Localized urticarial Generalized urticarial; angioedema Anaphylaxis
HeadacheMild, no treatment required Transient, moder ate; treatment 
requiredSevere; responds to initial narcotic 
therapyIntractable; requires repeated 
narcotic therapy
Fever: oral 37.7 to 38.5 C or 100.0 to 101.5 F 38.6 to 39.5 C or 101.6 to 102.9 F 39.6 to 40.5 C or 103 105 F >40 C or >105 F
FatigueNormal activity reduced <48 hours Normal activity decreased 25 to 50%; 
>48 hoursNormal activity decreased >50 %; 
cannot workUnable to care for self 
 
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
7912.7. Appendix 7:Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Pote ntial 
and Collection of Pregnancy  Information
12.7.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential
The list does not apply  to females of reproductive potential with same sex partners or for 
subjects who are and will continue to be abstinent from penile-vaginal intercourse on a 
long term and persistent basis, when this is their preferred and usual lifest yle.Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, postovulation methods) and 
withdrawal ar e not acceptable methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine device or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
4.Injectable progestogen [Hatcher , 2011]
5.Contraceptive vaginal ring [Hatcher , 2011]
6.Percutaneous contraceptive patches [Hatcher , 2011]
7.Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the clinic 
person nel’s review of subject’s medical records, medical examination and/or semen 
analysis, or medical history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
Contraceptive requirements for male subjects with female partners of reproductive 
potential (when applicable).
Male subjects with female partners of child- bearing potential must comply  with the 
following contraception requirements from [ADDRESS_776283] dose until 
completion of the Follow -up Visit .
8.Vasectom y with documentation of azoospermia. The documen tation on male sterility  
can come from the site personnel’s review of subject’s medical records, medical 
examination and/or semen anal ysis, or medical history  interview.
9. Male condom plus partner use of one of the contraceptive options below that meets 
the SOP effectiveness criteria including a <1% rate of failure per year, as stated in 
the product label:
Contraceptive subdermal implant
Intrauterine device or intrauterine s ystem 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
80Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011] 
Injectable progestogen [Hatcher , 2011]
Contraceptive vaginal ring [Hatcher , 2011]
Percutaneous contraceptive patches [Hatcher , 2011 ]
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.7.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study .
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
[ADDRESS_776284]’ s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The investigator 
will collect follow -up information on mother and infant, which will be forwarded to 
[COMPANY_004]. Generally , follow -up will not be required for longer than 6 to 8 weeks bey ond 
the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abo rtion is alway s considered to be an SAE and will be reported as 
such.
Any SAE occurring as a result of a post study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_387063] [ADDRESS_776285] who becomes pregnant while par ticipating: 
Will be withdrawn from the study .
The investigator will attempt to collect pregnancy  information on any  female partner 
of a male stud y subject who becomes pregnant while participating in this study. This 
applies only  to subjects who are random ized to receive study  medication. 
After obtaining the necessary  signed informed consent from the female partner 
directly , the investigator will record pregnancy  information on the appropriate form 
and submit it to [COMPANY_004] within 2 weeks of learning of the par tner’s pregnancy.
The partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to [COMPANY_004].  2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
81Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
8212.8. Appendix 8:Follow -up for Gastrointestinal Findings
Subjects who experience diarrh oea or enteritis should be evaluated with additional fecal 
occult blood tests and stool cultures as deemed appropriate b y the investigator. Any 
subject with a positive fecal occult blood test should be referred to a gastroenterologist 
for further evaluation at the discretion o f the investigator.
Subjects who experience an AE of diarrh oea or enteritis should have additional fecal 
occult blood testing, as well as a routine stool culture performed, which may include the 
recovery  of pathogenic bacteria such as Salmonella, Shigella ,Campylobacter, Yersinia, 
Vibrio, Staphylococcus aureus, Escherichia coli 0157, and enterohemorrhagic 
Escherichia coli.
In addition, if the subject meets the clinical criteria outlined in Append ix 9, Clostridium
diffic iletoxin detection should be conducted. 
Note: Additional testing is at the discretion of the investigator if it is believed the 
GIsigns/s ymptoms are due to cholinergic effects and/or if the GI signs /symptoms occur 
within 24 hours of the infusion. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
8312.9. Append ix 9:Clostridium Difficile Testing Procedure and 
Algorithm
 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
8412.10. Appendix 10:Country -Specific Requirements
No country -specific requirements exist. 2016N307631_00
2014N209329_00 CONFIDENTIA L
BTZ116849
8512.11. Appendix 11:Physiologically  Based Pharmacokinetic Model 
Input Parameters
Parameters Value References /Resources
Molecular weight 448.5 Investigator Brochure
Compound type Dibasic Technical Evidence Document
pKa 1 8.83 Adamantis
pKa 2 6.2 Calculated using Adamantis
cLog P 0.16 Calculated using Adamantis
Fu Plasma 0.67 Study # GlaxoSmithKline Document Number 2013N170240_00
Blood:Plasma ratio 0.95 Study # GlaxoSmithKline Document Number 2012N131922_00
Vdss 1.30 Predicted Full PBPK with addtional organ compartment and Kp scalar 0.7
Additional o rgan Kp100 Predicted value of pi[INVESTIGATOR_589346] #
GlaxoSmithKline Document Number 2012N156820_00
CYP3A4 f m 0.25
CYP3A4 CL int 
(L/min/pmole P450)0.0434 SimCYP calculation based on CLi.v. of 43 L/hr with measured renal 
clearance of 16 L/hr  with CYP3A4 fm =0.25
Additional HLM CL int
(l/min/mg protein)9.00 SimCYP calculation based on CLi.v. of 43 L/hr with measured renal 
clearance of 16 L/hr with CYP3A4 fm=0.25
CYP = cytochrome 450, Fu = f raction unbound; Vdss = volume of distribution at steady state; Kp = equilibrium 
partition coefficient of drug; PBPK = physiologically based pharmacokinetic model; QWBA =quantitative whole -body 
autoradioluminography 2016N307631_00